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ABSTRACT OF DISSERTATION 
 
ROLES OF ABCG5 ABCG8 CHOLESTEROL TRANSPORTER IN LIPID 
HOMEOSTASIS 
 
The ABCG5 ABCG8 (G5G8) sterol transporter promotes cholesterol secretion 
into bile and opposes dietary sterol absorption in the small intestine. An 
emerging body of literature suggests that G5G8 links sterol flux to various risk 
factors for metabolic syndrome (MetS) and nonalcoholic fatty liver disease 
(NAFLD). Therapeutic approaches that accelerate G5G8 activity may augment 
reverse cholesterol transport (RCT) and provide beneficial effects in the 
prevention and treatment of cardiovascular and liver disease.  
 
Mice lacking leptin (ob/ob) or its receptor (db/db) are obese, insulin resistant in 
part due to the reduced levels of hepatic G5G8 and biliary cholesterol. The 
underlying mechanisms responsible for the reduced G5G8 protein expression in 
these mice may provide a clue to the drug development for this target. My 
studies show that neither acute leptin replacement nor liver-specific deletion of 
leptin receptor alters G5G8 abundance or biliary cholesterol. Similarly, hepatic 
vagotomy has no effect on G5G8 expression. Conversely, expression of the ER 
chaperone, GRP78, rescues G5G8 in db/db mice.  
 
Previous studies suggest an interdependent relationship between liver and 
intestine for cholesterol elimination. A combination therapy that increases G5G8-
mediated biliary cholesterol secretion and simultaneously reduces intestinal 
absorption is likely to act additively in cholesterol elimination. My studies show 
that treatment with ursodiol (Urso) increases hepatic G5G8 protein and both 
biliary and fecal sterols in a dose-dependent manner. Ezetimibe (EZ), a potent 
inhibitor of intestinal cholesterol absorption, produces an additive and dose-
dependent increase in fecal sterol excretion in the presence of Urso. However, 
the stimulatory effects of both Urso and Urso-EZ are not G5G8-dependent.  
 
  Beyond increasing G5G8 protein expression and biliary cholesterol secretion, my 
studies also show that Urso stimulates ileal FGF15 expression in mice. Our data 
of the stimulated ileal FGF15 expression in LIRKO and reduced hepatic G5G8 
protein levels in Atsb KO mice both indicate the previous unrecognized role of 
FGF15/19 in the regulation of G5G8 and its activity. Indeed, this is subsequently 
confirmed by our results from the direct test of recombinant human FGF19 on 
G5G8. Thus, FGF15/19 may provide an alternative strategy in drug development 
to target G5G8 activity and accelerate cholesterol elimination. 
 
 
KEYWORDS: Reverse cholesterol transport, G5G8, GRP78, Ursodiol, Ezetimibe, 
FGF15/19 
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CHAPTER 1: INTRODUCTION 
 
The metabolic syndrome (MetS) is a constellation of interrelated risk factors 
including obesity, atherogenic dyslipidemia, and elevated blood glucose and 
pressure with insulin resistance as the central source of pathogenesis. This 
symptom identifies individuals at an increased risk for developing type II 
diabetes and cardiovascular disease (CVD), the number one cause of global 
mortality. Patients with MetS have 50-60% higher risk for CVD than those 
without [1]. Thus, MetS is an important risk factor for the incidence and 
mortality of CVD. 
MetS has deleterious effects on many organs, the liver being one of them. There 
is increased evidence that NAFLD is now considered the hepatic manifestation of 
MetS and has been identified as a common feature in patients with the MetS. 
NAFLD involves a spectrum of liver-related disorders that range from simple 
steatosis to steatohepatitis (NASH), fibrosis, and cirrhosis. It is the most common 
liver disease that affects 20%-30% of the US population and hence is increasingly 
recognized as a major contributor to the burden of chronic liver disease world-
wide. MetS and NAFLD appear to have a common pathogenesis, arising from 
insulin resistance and abdominal obesity. Treatment of MetS may have a 
significant impact on progression of NAFLD, and therapeutic approaches 
treating the underlying risk factors of MetS appear to be valid options in treating 
NAFLD/NASH. 
2 
 
Given the progressively increasing prevalence and incidence of MetS and 
NAFLD, such conditions have gained worldwide attention and become major 
public health problems that are approaching epidemic proportions globally. The 
general lack of knowledge of pathogenesis prevents us from refining the most 
efficient therapies for individuals with MetS and NAFLD. The major goal of 
clinical management is to reduce the risks for CVD. The prime emphasis is given 
to the effective lifestyle interventions. If lifestyle change is not sufficient, 
pharmacological therapies are incorporated to the regimen. For example, statins 
and ezetimibe (EZ) have been used to target cholesterol synthesis and 
absorption, respectively, to reduce plasma low-density lipoprotein cholesterol 
(LDL-C) and lower the risk of CVD. However, an emerging body of work 
suggests that the flux of cholesterol through lipoproteins is more relevant to 
CVD than their absolute levels in plasma. Consequently, there has been intensely 
increased interest in strategies aimed at enhancing sterol flux from peripheral 
tissues to liver for ultimate excretion into feces, a process termed reverse 
cholesterol transport (RCT). 
A substantial amount of work has been devoted to the conceptual approaches to 
augment RCT by improving cellular cholesterol efflux from peripheral cells, 
enhancing the functionality of circulating high-density lipoprotein (HDL), and 
increasing hepatic uptake of returned cholesterol. Relatively little effort has been 
geared at developing therapeutic approaches to target the final step of RCT. 
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Recent studies suggest that cholesterol taken up by hepatocytes is secreted into 
bile via the apical membrane sterol transporters ABCG5 and ABCG8 (G5G8), 
which form a functional heterodimeric complex that ties the link of sterol flux to 
metabolic disease [2-4]. The goal of this dissertation thesis is to understand the 
mechanisms responsible for the post-transcriptional regulation of G5G8 in vivo 
such that appropriate therapeutics could be employed to accelerate cholesterol 
elimination in the treatment of liver and cardiovascular disease.   
Overview of the metabolic syndrome (MetS) and its hepatic manifestation: 
nonalcoholic fatty liver disease (NAFLD) 
The clustering of several metabolic and pathophysiological cardiovascular risk 
factors (e.g., insulin resistance, abdominal obesity, dyslipidemia, impaired 
glucose tolerance, hypertension) was firstly discussed by Dr. Reaven in his 
Banting lecture in 1998 [5]. He named this clustering Syndrome X and recognized 
it as a multidimensional risk factor for CVD. Since then, this clinical symptom 
has been given different names (e.g., insulin resistance syndrome, metabolic 
syndrome X). It is now widely referred to as MetS in clinical practice.  
The prevalence of MetS ranges largely from less than 10% to 84%, depending on 
the region, composition (e.g., age, sex, and race) of the population studied, and 
the definition and criteria of the syndrome used [6, 7]. But in general, the 
International Diabetes Federation (IDF) estimates that approximately 25% of the 
world’s adult population has MetS [8]. The increasing prevalence of MetS is also 
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associated with the substantial progression of diabetes and CVD. Thus, MetS has 
received a lot of focused attention as a major public health concern. 
Components of metabolic syndrome: underlying and metabolic risk factors 
The MetS encompasses a group of interrelated risk factors that together confers 
an increased risk of type II diabetes and CVD. The components of MetS include 
both underlying and metabolic risk factors [9, 10]. The predominant underlying 
risk factors, which provoke the metabolic risk factors, are thought to be 
abdominal obesity and insulin resistance [5, 11-14]. The major metabolic risk 
factors are mostly widely recognized as atherogenic dyslipidemia, raised plasma 
glucose, and hypertension [9]. 
Underlying risk factors: abdominal obesity and insulin resistance 
The enormous scope of epidemiological research has shed light on the positive 
relationship between obesity and MetS. This is largely based on the possible 
ability of obesity to engender insulin resistance. One theory postulated by 
Reaven and others holds that insulin resistance is the core cause of MetS. Hence, 
this symptom was also widely known as insulin resistance syndrome. However, 
many details of the mechanisms, by which obesity causes systemic insulin 
resistance, have not been adequately elucidated. There is also an explosive 
increase in evidence supporting that insulin resistance is an etiological aspect of 
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obesity. Therefore, the unraveled cause-and-effect relationship between obesity 
and insulin resistance renders both of them the underlying risk factors for MetS. 
Abdominal obesity 
 The National Cholesterol Education Program’s Adult Treatment Panel III report 
(ATP III) considered the “obesity epidemic” as the driving force that underlies 
the rising prevalence of MetS and defined MetS as a clustering of metabolic 
complications of obesity, especially abdominal obesity [14-17]. This statement 
needs to be in agreement with the insulin resistance theory. Abdominal obesity 
(or central obesity, upper-body obesity) is the form of obesity most likely to be 
associated with MetS and contribute to the increased risk of type II diabetes and 
CVD [17-21]. It presents as increased waist circumference in clinical practice. The 
ATP III defined the thresholds of waist circumference for the identification of 
MetS to be 102 cm for men and 88 cm for women, respectively [15].  
The abdominal obesity strongly correlates with insulin resistance. This positive 
correlation is largely due to the dysfunctional adipose tissues. However, the 
underlying mechanisms about fat and insulin resistance in abdominal obesity 
have not been sufficiently articulated. One theory is that the excess upper-body 
fat releases elevated levels of nonesterified fatty acids (NEFA) [22]. The acute 
exposure to unusual high levels of NEFA overloads liver and skeletal muscles 
with lipids [23-25]. This ectopic lipid accumulation in sites other than adipose 
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tissue seemingly supports abdominal obesity as a causal factor for developing 
insulin resistance and increased risk of MetS.  
The adipocyte is now recognized as a secretory cell that has a major endocrine 
function [26, 27]. The adipokine is a collective name given to various peptide 
hormones and protein factors including leptin, adiponectin, tumor necrosis 
factor-alpha (TNFα), interleukin-6 (IL-6), C-reactive protein (CRP), plasminogen 
activator inhibitor-1 (PAI-1), and others that are secreted or synthesized by the 
adipocyte [28-31]. An alternative hypothesized mechanism is that in abdominal 
obesity, the abnormal production of several adipokines by the intra-abdominal 
adipocytes may exert harmful effects to insulin sensitivity and modify risks for 
MetS and CVD. The abnormalities may include increased production of TNFα, 
IL-6, CRP, PAI-1, and at the same time reduced adiponectin levels [32-34].  
Insulin resistance 
Insulin is a critical hormonal regulator of glucose and lipid homeostasis among 
the major insulin-responsive organs including liver, fat, and muscle. It binds to 
and activates the insulin receptor tyrosine kinase, which in turn phosphorylates 
insulin receptor substrate (IRS) proteins (Irs1 and 2) and initiates two branches of 
insulin signaling events [35]. One is the activation of phosphatidylinositol 3-
kinase (PI3K), which mediates insulin’s metabolic effects. The other one is the 
activation of mitogen activated protein (MAP) kinase, which is primarily 
associated with the mitogenic effects of insulin.  
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The action of insulin to reduce plasma glucose results from the suppression of 
gluconeogenesis in liver and the increase of glucose uptake into fat and muscle 
[36, 37]. The phosphorylation of forkhead box protein O1 (FOXO1), a 
transcription factor that mediates insulin actions through PI3K pathway, 
diminishes gluconeogenesis [36]. The action of insulin to promote TG storage is 
derived from multiple mechanisms. In liver, insulin activates the sterol 
regulatory element binding protein (SREBP)-1c, a transcription factor which 
enhances the transcription of genes involved in fatty acid and TG synthesis 
(lipogenesis) [37-40]. The newly synthesized TGs are secreted from liver via very 
low density lipoprotein (VLDL), a lipoprotein that delivers TGs to fat for storage 
and muscle for energy expenditure. In fat, insulin stimulates the differentiation 
of preadipocytes to adipocytes. In mature adipocytes, insulin facilitates the 
uptake of VLDL-derived fatty acids, promotes lipogenesis, and inhibits lipolysis 
[41]. 
Insulin resistance usually refers to a state of reduced responsiveness to the action 
of insulin on glucose uptake, metabolism, or storage. It is not established that 
insulin resistance per se plays a causal role in MetS due to the fact that it is 
difficult to identify a unique role of insulin resistance from a complex interaction 
of many factors. But it is well accepted that insulin resistance in obesity is the 
underlying cause for MetS [42]. Although insulin resistance is pronounced in 
obesity, MetS, and type II diabetes, it is not to say that all of the insulin actions 
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are diminished in individuals with such conditions. For example, while insulin-
stimulated glucose transport and metabolism are decreased in fat and muscle 
and the suppression of gluconeogenesis in liver is impaired, hepatic lipogenesis 
is still sensitive to insulin and is driven to excess by the commentary 
hyperinsulinemia [37]. To dissect the role of insulin resistance in the molecular 
and pathophysiological basis of MetS, Kahn and colleagues generated the liver-
specific insulin receptor knockout (LIKRO) micel, which initiated a discussion 
about the pathogenic paradox in selective versus total insulin resistance in liver. 
Selective insulin resistance is the typical insulin resistance defined clinically in 
terms of the failure of insulin to maintain glucose homeostasis. However, insulin 
continues to activate lipogenesis, producing a combination of hyperglycemia and 
hypertriglyceridemia. These are characteristic features of humans and mice with 
MetS and type II diabetes. The extensively used mouse models of MetS and 
insulin-resistant type II diabetes are ob/ob and db/db mice, due to the lack of leptin 
or its receptor, respectively. Both strains of mice have increased food intake 
attributed to the deficiency of leptin, a neutral hunger suppressant. They are 
massively obese and hyperphagic and exhibit a triad of hyperglycemia, 
hyperinsulinemia, and hypertriglyceridemia [43, 44]. 
Total hepatic insulin resistance refers to a defect in hepatic insulin signaling due 
to the ablation of the hepatic insulin receptor gene. It implies that all processes 
regulated by hepatic insulin signaling become resistance to insulin in parallel 
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with glucose metabolism. Paradoxically, despite hyperglycemia, neither humans 
with insulin receptor mutations nor LIRKO mice manifest hypertriglyceridemia 
or hepatic steatosis [45-48]. This is largely due to that insulin fails to stimulate 
lipogenesis. Based on this paradox, Biddinger and colleagues concluded that 
hepatic steatosis and hypertriglyceridemia are not directly attributed to insulin 
resistance, and should be considered as distinct features contributing to the 
pathogenesis of MetS [49]. However, due to the complex interplay among insulin 
resistance, steatosis, and hypertriglyceridemia, it remains uncertain whether this 
argument is true. 
Another paradox is also associated with the two stages of insulin resistance. The 
complete hepatic insulin resistance in LIRKO mice produces increased biliary 
cholesterol secretion and cholesterol gallstones. This links insulin resistance to 
biliary lipid metabolism. Various features of the selective insulin resistant ob/ob 
and db/db mice also potentiate the risk of gallstone formation. However, they 
manifest paradoxically low biliary cholesterol saturation. This puzzle will be 
particularly addressed in the Chapter 2 of this dissertation.  
Metabolic risk factors 
As stated earlier, the major metabolic risk factors comprise atherogenic 
dyslipidemia, elevated plasma glucose, and hypertension. Each of them conveys 
increased risk of MetS even when only marginally abnormal. Atherogenic 
dyslipidemia consists of a triad of lipoprotein abnormalities implicated as 
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independent atherogenic factors. These abnormalities include increased plasma 
concentrations of TG and small, dense LDL particles, and decreased high-density 
lipoprotein cholesterol (HDL-C) [50]. The LDL particle size is not corrected with 
the LDL-C, but it shows striking correlations with the TG and HDL-C 
concentrations [51]. Thus, the TG/HDL-C ratio is beneficial for assessing the 
presence of small LDL [51]. As a characteristic feature of obesity and insulin 
resistance, atherogenic dyslipidemia has emerged as a critical risk factor for MetS 
and CVD. Other well established metabolic risk factors are elevated plasma 
glucose and hypertension. Multiple mechanisms have been postulated to explain 
how increased plasma glucose may promote atherosclerosis, but none is 
particularly well established. Regardless, once MetS compounds type II diabetes, 
risk and incidence for CVD events increase further more.  
Clinical outcomes of MetS 
The major clinical outcome of MetS is CVD, the most dreaded complication of 
this disease [1, 52-55]. Reaven and others postulated that insulin resistance is the 
essential cause of MetS [5, 56]. Hence, insulin resistance syndrome was also 
commonly used to name the clustering of risk factors. The majority of people 
with MetS have insulin resistance. Insulin resistance and the compensatory 
hyperinsulinemia predispose to type II diabetes. Thus, individuals with MetS are 
also susceptible to type II diabetes, another major risk factor for CVD [57-59]. 
When type II diabetes emerges, CVD risk rises even more [60]. Beyond CVD and 
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type II diabetes, a variety of other conditions are notably present in individuals 
with MetS; one of them is NAFLD [61-65]. There is increased evidence that 
NAFLD is now considered the hepatic manifestation of MetS and has been 
identified as a common feature in patients with the MetS [63, 64]. Recent studies 
have indicated that NAFLD is also intensely associated with increased risk of 
CVD [66, 67].   
Nonalcoholic fatty liver disease (NAFLD) 
NAFLD involves a wide spectrum of fat-induced liver-related disorders that 
range from relatively benign simple steatosis to NASH with fibrosis and 
scarring, which can further progress to the devastating conditions like cirrhosis 
or eventually hepatocellular carcinoma (HCC) [68]. Steatosis is defined as the 
presence of fat in more than 5%-10% of liver weight. It is usually considered 
benign and reversible, but can progress to NASH. NASH, the most extreme stage 
of NAFLD, is distinguished from steatosis by the features including hepatocyte 
injury, inflammation, and fibrosis [68]. Between 10-29% of individuals diagnosed 
with NASH may develop cirrhosis within 10 years and 4-27% among them may 
develop HCC eventually [68]. NAFLD is a growing health problem with an 
incidence ranging from 17-33% and 5-17% for its more severe expression, NASH 
[69]. It is estimated that NAFLD/NASH will increase medical costs by 26% [70].  
Available data from epidemiological, experimental, and clinical studies support a 
close association between NAFLD and MetS. For example, 90% of subjects with 
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NAFLD have at least one risk factor of MetS, and 33% of them have all the 
features of MetS. In 271 nondiabetic subjects, liver fat content is significantly 
increased in subjects with MetS as compared with those without the syndrome 
[71]. In a prospective observational study containing 4401 apparently healthy 
Japanese, participants diagnosed with MetS have 4 to 11 folds higher risk for 
future NAFLD [72]. Additionally, if NAFLD and MetS coexist, disease regression 
is less likely [72]. In another study containing 16,486 Taiwanese NAFLD patients, 
the presence of severe fatty liver is significantly correlated with the prevalence 
and degree of hypertension, abnormal TG and glucose metabolism, all of which 
are metabolic risk factors for MetS [73]. NAFLD ranging from steatosis to NASH 
might represent another characteristic feature of MetS. Accumulating data 
suggest that MetS and NAFLD seem to share common pathophysiological 
mechanisms, with abdominal obesity and insulin resistance as the key 
pathogenic factors.  
Pathogenesis of NAFLD/NASH 
The majority of NAFLD subjects are obese and insulin resistant. The regulation 
of glucose and lipid metabolism involves a complicated interplay among the 
major metabolic tissues including liver, fat, and muscle. Obesity, insulin 
resistance, inflammation, genetic factors, over-nutrients, and unhealthy lifestyle 
may all paly essential roles in the development of NAFLD. While our knowledge 
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of the pathogenesis of NAFLD has extensively increased over the past two 
decades, many uncertainties remain to be intensely investigated. 
The central mechanisms responsible for NAFLD similar to MetS are thought to 
be abdominal obesity and insulin resistance. The typical site for lipid storage is 
the subcutaneous fat. However, when lipids are accumulated to excess in these 
fat depots, they are likely to be redistributed to other sites for deposit including 
abdominal fat depot and insulin-sensitive tissues such as liver and muscle [74]. 
When the acquisition of lipids within in liver exceeds the normal lipid turnover, 
hepatic steatosis arises. In the state of insulin resistance, principally in the context 
of abdominal obesity and MetS, the possible sources for the pathophysiology of 
hepatic steatosis may include: (1) increased influx of NEFA to liver; (2) increased 
de novo lipogenesis in liver; (3) reduced rate of β-oxidation; and (4) reduced TG 
export from liver in the form of VLDL. The increased influx of NEFA (60%) is 
considered as the largest contributor to steatosis in individuals with NAFLD [75]. 
This is predominantly due to the dietary intake of fat and increased lipolysis 
within abdominal fat. Approximately 25% of the TG accumulated in the liver of 
NAFLD individuals is derived from the de novo lipogenesis. This is mainly due 
to the increased activity of SREBP1c and carbohydrate response element-binding 
protein (ChREBP), both of which regulate the expression of genes involved in the 
lipogenic pathway. TGs are re-packaged within VLDL and exported from liver. 
Each VLDL particle contains only one molecule of apolipoprotein B (apoB), the 
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synthesis of which is a rate-limiting step in VLDL production. Under normal 
condition, insulin targets apoB for intracellular degradation, whereas in the state 
of insulin resistance, the compensated hyperinsulinemia may alter apoB 
synthesis or promote its degradation and thereby decreasing TG export in VLDL 
[76, 77].  
The pathophysiological basis for the transition from steatosis to NASH is 
multifactorial and not fully understood. A “two-hit” theory was firstly 
postulated by Day to explain the NASH pathogenesis [78]. The disequilibrium 
between fat acquisition and removal within hepatocytes causing simple steatosis 
comprises the “first hit”, and the susceptibility of a fatty liver to a separate injury 
(“second hit”) results in inflammation, fibrosis, and apoptosis [78]. A variety of 
factors may be considered the “second hit” and contribute to the pathogenesis of 
NASH, such as oxidative stress, inflammatory cytokine and adipokine alteration, 
mitochondrial dysfunction, fatty acid lipotoxicity, innate immunity, and many 
others [78-84].  
New suspects in the pathogenesis of NAFLD/NASH: Endoplasmic reticulum 
(ER) stress 
Recently, accumulating data have indicated that the endoplasmic reticulum (ER) 
stress plays a crucial role in both the development of steatosis and the 
progression to NASH [85, 86]. ER is a central hub for the synthesis and post-
translational modification of secretory and membrane proteins, lipid 
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biosynthesis, oxidative metabolism, and intracellular calcium homeostasis. 
Newly synthesized proteins in the ER lumen require the assistance of chaperone 
proteins to undergo post-translational modifications such as N-glycosylation and 
disulfide bond formation. The 78-kD glucose-regulated/binding 
immunoglobulin protein (GRP78) is one of the major ER chaperones particularly 
essential to the regulation of ER function due to its role in protein folding and 
assembly, targeting aberrant proteins for degradation, and controlling activation 
of ER stress sensors. When there are metabolic disturbances that compromise ER 
function, such as excessive protein synthesis, accumulation of unfolded or 
misfolded proteins, calcium depletion, or perturbation of redox status, the whole 
organelle enters into a state called “ER stress”.  
As a recovery and adaptation mechanism, the ER responds to ER stress by 
activating a series of signaling pathways, collectively named the unfolded 
protein response (UPR), to adjust to the protein-folding demand and promote 
cell survival and adaptation [87]. Three distinct stress sensors including protein 
kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring 
enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) are well 
characterized to monitor the imbalance between protein load and folding 
capacity within ER (Fig 1.1) [88-90]. Under the normal physiological condition, 
GRP78 binds to the luminal domains of the three transducers remaining them in 
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the inactive state. Upon stress conditions, GRP78 is displaced from PERK, IRE1, 
and ATF6 resulting in their activation.  
Upon dissociation from GRP78, PERK oligomerizes, autophosphorylates, and 
phosphorylates eukaryotic initiation factor 2 alpha (eIF2α) [89]. Phosphorylated 
eIF2α leads to a global repression of mRNA translation and reduced flux of 
protein entering ER to alleviated ER stress [91]. An exception is the activating 
transcription factor 4 (ATF4). It requires eIF2α phosphorylation to enhance its 
mRNA translation to regulate the downstream UPR target genes such as C/EBP 
homologous protein (CHOP) [92]. Upon ER stress conditions, IRE1 dimerizes 
and autophosphorylates to be activated. Activated IRE1 results in splicing of X-
box binding protein 1 (XBP1) mRNA [93, 94]. Spliced XBP1 selectively 
upregulates chaperone proteins such as GRP78 and GRP94 to cope with 
increased protein-folding demand. ATF6 is a membrane bound transcription 
factor. Dissociation of GRP78 from ATF6 leads to its translocation to Golgi where 
it is cleaved by site 1 and site 2 proteases, generating a soluble form of ATF6 [95]. 
Upon entry to the nucleus, this processed form of ATF6 activates UPR target 
genes involved in protein folding and degradation. Postponed or inadequate 
UPR responses to ER stress may produce pathological consequences, including 
abnormal lipid accumulation, insulin resistance, inflammation, and apoptosis, all 
of which play key roles in the pathogenesis of NAFLD. 
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Figure 1.1 A diagram of the initiation of the UPR by unfolded or misfolded 
proteins. GRP78 releases from its binding state of PERK, IRE1, and ATF6 in 
response to the overwhelming accumulation of mal-folded proteins and triggers 
the UPR signaling. Dissociation of GRP78 from PERK results in the 
phosphorylation of eIF2α, which inhibits translation and leads to cell cycle arrest. 
The activated domain of IRE1 results in cleavage of XBP1, while activated ATF6 
is transported to the Golgi, cleaved by site 1 and site 2 proteases to produce an 
active 50kDa form of ATF6. The cleaved XBP1 and the processed form of ATF6 
selectively upregulate chaperone proteins to manage increased protein-folding 
demand.  
 
The activation of ER stress was firstly described by Ozcan and colleagues in the 
livers of both diet-induced and genetic models of NAFLD in the setting of 
obesity [96]. In both models, phosphorylations of PERK and eIF2 as well as 
GRP78 expression were increased indicating activated UPR signaling [96]. Since 
then, these observations have been confirmed in other NAFLD/NASH animal 
models in the presence and absence of obesity [97-99]. Later, several UPR 
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components were reported to be induced in the livers of human subjects with 
NAFLD or NASH [100]. However, the precise contribution of ER stress to the 
development of NAFLD is not fully understood.  
Hepatic steatosis, which is caused by the disequilibrium of lipid accumulation 
and removal as stated earlier, is the first step for the development of NAFLD. It 
is well accepted that a variety of components of the UPR signaling interfere with 
hepatic lipid metabolism by promoting lipogenesis and inhibiting VLDL 
production and secretion [101-108]. Hepatic lipogenesis is also dependent on the 
insulin-stimulated activation of SREBP1c despite the prevailing insulin 
resistance. Thus, ER stress can also indirectly promote hepatic TG accumulation 
by exacerbating insulin resistance. Several mechanisms are seemingly 
responsible for the effect of ER stress on hepatic insulin resistance. For example, 
Ozcan and colleagues have published data showing that ER stress promotes 
hepatic insulin resistance through IRE1α-mediated hyperactivation of c-Jun N-
terminal kinase (JNK) and the serine phosphorylation of insulin receptor 
substrate-1 [96]. Additional support is derived from the PERK-mediated 
phosphorylation of FOXO [109]. Though further mounting evidence also 
indicates the impact of ER stress on insulin resistance, the exact contribution of 
ER stress to insulin resistance in NAFLD is still unclear. Other mechanisms by 
which ER stress potentiate NAFLD may include the production of reactive 
oxygen species (ROS), the activation of JNK, nuclear factor kappa-light-chain-
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enhancer of activated B cells (NF-κB), and CHOP, which are actively involved in 
the inflammatory and apoptotic processes [110].   
Ozcan and colleagues reported that chemical chaperones such as 4-Phenyl 
butyric acid (4-PBA) and tauroursodeoxycholic acid (TUDCA) alleviated ER 
stress both in vitro and in vivo. Administration of such chaperones to ob/ob mice 
alleviated ER stress, resulting in improved insulin sensitivity and glycemia as 
well as a resolution of steatosis [111]. Foufelle and colleagues reported that 
supplementation of chaperone protein GRP78, another approach to alleviate ER 
stress, also restored insulin sensitivity in ob/ob mice. Interestingly, the 
overexpression of GRP78 also inhibited SREBP1c activation, thereby reducing 
lipogenesis and improving the status of steatosis [112].  
New suspects in the pathogenesis of NAFLD/NASH: Free cholesterol (FC) 
The excess hepatic accumulation of lipids, particularly TG, as the key defect in 
NAFLD has been given the most intense investigation. However, two lipidomic 
studies have shown that apart from TGs, free cholesterol (FC) is also intensively 
accumulated in human NAFLD/NASH subjects [113, 114]. Thus, more efforts 
have been made to confirm this finding in different NAFLD/NASH models and 
to investigate the role of FC in the pathogenesis of NAFLD/NASH.  
Cholesterol is a fundamental constituent of mammalian cell membranes and also 
serves as the fuel for the biogenesis of bile acids, vitamin D, and steroid 
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hormones. There are two mechanisms for the body to acquire a sufficient pool of 
cholesterol to maintain its normal function [115]. One is the intestinal absorption 
of dietary cholesterol by Niemann-Pick C1-like 1 (NPC1L1) transporter. 
Cholesterol is transported in the circulation predominantly in the form of 
cholesteryl ester (CE) carried by lipoproteins. Upon absorption, dietary 
cholesterol is transported from the intestine through the circulation within 
chylomicron (CM) and delivered to liver by CE-rich CM remnant (CMR) via 
endocytosis mediated by LDL receptor (LDLR) or LDLR related protein 1 (LRP-
1) (Fig 1.2) [116]. However, in the context of NAFLD, the excess intake of dietary 
cholesterol may act synergistically with fat to facilitate the progression of 
NAFLD to NASH. For example, adding cholesterol to a high-fat (HF) diet in 
C57BL/6J mice leads to significantly more profound hepatosteatosis, 
inflammation, and fibrosis resembling human NASH [117]. Similarly, in LDLR 
deficient mice, adding cholesterol to a HF, high-sucrose diet exacerbates the 
development of insulin resistance and steatosis resulting in NASH [118]. 
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Figure 1.2 Overview of cholesterol metabolism. The body acquires cholesterol 
by two mechanisms including the intestinal absorption of dietary cholesterol and 
the de novo cholesterol biosynthesis. The liver is a central organ in maintaining 
cholesterol homeostasis by balancing de novo cholesterol synthesis and hepatic 
uptake of plasma lipoproteins from the circulation against bile acid synthesis and 
the excretion of hepatic cholesterol and bile acid excretion into bile. C, 
cholesterol; CE, cholesteryl ester; NPC1L1, Niemann-Pick C1-like 1 transporter; 
CM, chylomicron; CMR, chylomicron remnant; HMGCR, 3-hydroxy-3-
methylglutary CoA reductase; VLDL, very low-density lipoprotein; LDL, low-
density lipoprotein; HDL, high-density lipoprotein, CYP7A1, cholesterol 7alpha-
hydroxylase. 
 
The other way for the body to obtain cholesterol is through de novo cholesterol 
synthesis (Fig 1.2). It begins from acetyl-CoA and acetoacetyl-CoA, which are 
converted to 3-hydroxy-3-methylglutary CoA (HMG-CoA) by HMG-CoA 
synthase (HMGCS). The HMG-CoA reductase (HMGCR) subsequently catalyzes 
the irreversible and rate-limiting reaction by converting HMG-CoA to 
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mevalonate and is thus the target of the widely utilized cholesterol-lowing drugs 
collectively termed as the statins. Mevalonate is then converted to isopentenyl 
pyrophosphate (IPP), squalene, lanosterol, and eventually cholesterol.  
The rate of cholesterol biosynthesis is relatively higher in liver, intestine, and 
adrenal glands. It is under tight transcriptional control via SREBP2 [39, 119]. 
SREBP cleavage-activating protein (SCAP), as a sterol sensor and escort protein, 
forms a protein complex with SREBP2. In response to deprivation of sterols, 
SCAP escorts SREBP2 from ER to Golgi where SREBP2 is processed into an 
active transcription factor that upregulates the expression of genes involved in 
cholesterol synthesis, e.g., HMGCR, and uptake, e.g., LDLR. Conversely, excess 
sterols accumulating in the ER membrane result in a conformational change of 
SCAP, which allows it to bind to the insulin-induced gene proteins (Insig1 or 2), 
the ER resident membrane proteins that prevent the SCAP/SREBP complex from 
migrating to the Golgi. Thus, HMGCR is rapidly degraded, resulting in the 
termination of cholesterol synthesis. 
The liver is a central organ in maintaining cholesterol homeostasis by balancing 
de novo cholesterol synthesis and hepatic uptake of plasma lipoproteins from the 
circulation against bile acid synthesis and the excretion of hepatic cholesterol and 
bile acid into bile (Fig 1.2). Newly synthesized cholesterol in liver, as well as 
dietary cholesterol delivered to liver that exceeds the hepatic tolerance, is re-
secreted to the circulation via VLDL. Secreted VLDL is converted to 
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intermediated IDL and further LDL through the hydrolysis action of endothelial 
cell-associated lipoprotein lipase (LPL). Cholesterol in the circulation and 
acquired from peripheral cells particularly macrophages can be returned to liver 
through HDL for biliary and fecal excretion, the whole process of which is 
widely known as reverse cholesterol transport (RCT) [120]. Ultimately, 
cholesterol is secreted into bile as FC or as bile salts following conversion to bile 
acids mediated by cholesterol 7alpha-hydroxylase, a rate-limiting enzyme 
encoded by CYP7A1 [121-123]. 
The disruption of hepatic cholesterol homeostasis by excess FC accumulation has 
been recently appreciated as a possible player in the pathogenesis of 
NAFLD/NASH. For example, in a mouse model of Alström syndrome (Alms1 
mutant or foz/foz mice), an elevation in hepatic FC due to an increase in hepatic 
uptake and a decrease in biliary elimination is thought to play a contributing role 
in the development of NASH [124]. A recent human study also highlighted the 
emerging role of FC in the pathogenesis of NAFLD/NASH by determining the 
expression of SREBP2 and HMGCR in liver [114]. Both SREBP2 and HMGCR 
were overexpressed in subjects with NAFLD compared to those with normal 
liver histology. Furthermore, the expression of SREBP2 was much higher in 
subjects with NASH compared to those with simple steatosis, suggesting that the 
progressive increase in hepatic FC is positively associated with the induction of 
SREBP2 [114].  
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Based on the emerging role of excess FC in the pathogenesis of NAFLD/NASH, 
reducing the intracellular FC levels provides a new therapeutic target for the 
treatment of the disease. In the third chapter of this dissertation, a novel 
pharmacological strategy for the treatment of NAFLD/NASH was proposed and 
tested in vivo to promote the sterol flux into bile and eventually into feces for 
elimination  
Clinical management of MetS and NAFLD 
Given the progressively increasing prevalence and incidence of MetS and 
NAFLD, such conditions have gained worldwide attention and become major 
public health problems that are approaching epidemic proportions globally. 
Intense investigations are still needed to clarify the pathogenesis of MetS and 
NAFLD so as to establish effective treatments for both of them and ultimately 
reduce the risk and incidence of CVD.  
The primary goal of clinical management in patients with MetS and NAFLD is to 
reduce the risk factors for CVD. The first-line intervention is directed toward 
mitigating the modifiable, underlying risk factors through lifestyle change [15]. 
For example, the weight reduction reinforced with regular exercise and diet 
modification decreases the effect of insulin resistance, lowers plasma cholesterol 
and TG, raises HDL-C, and reduces plasma glucose and pressure. If lifestyle 
change doesn’t reach the expected outcome, pharmacological therapies are 
usually incorporated to the regimen.  
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Insulin resistance, as an underlying cause for MetS and NAFLD, carries 
increased risk of development of diabetes and CVD. Therefore, it as a target has 
caught the imagination of the pharmaceutical industry. Both Metformin and 
insulin sensitizer thiazolidinedione (STZ) have been approved for treatment of 
type II diabetes. They reduce insulin resistance and apparently modify several 
metabolic risk factors [125-129]. However, the heterogeneity of the studies 
conducted to evaluate their efficiency in insulin-resistant NAFLD patients 
prevents us from reaching firm conclusions about their effectiveness at reversing 
the disease and developing standard treatment guidelines [130]. Additionally, 
the clinical trials using these insulin sensitizers to prove reduction of CVD are 
lacking [15].  
The current therapeutic strategies to reduce the risk factors of CVD are aimed 
primarily at lowering plasma LDL-C concentration by using lipid-lowering 
agents. Beyond lifestyle interventions and insulin sensitizers, the lipid-lowering 
drug therapies are also widely employed in the treatment of MetS and NAFLD. 
Statins, which act as HMGCR inhibitors, are effective lipid-lowering agents. They 
reduce cholesterol synthesis, decrease the intracellular cholesterol pool, and 
stimulate the compensatory upregulation of LDLR to lower LDL-C. The 
beneficial effects of statins in lowering LDL-C appear to be particularly 
important for reducing risk of CVD in patients with MetS. Statins have also been 
used in small clinical trials to evaluate the efficacy in NAFLD/NASH [131, 132]. 
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For example, in a small Japanese study including 31 patients with biopsy-proven 
NASH with dyslipidemia, the NASH-related metabolic parameters including 
fibrosis improved with the atorvastatin therapy in some patients. However, up to 
25%of patients had progression of fibrosis over the 2-year period [131]. The 
efficacy of statins for the treatment of NAFLD/NASH is still under debating. 
Many physicians are concerned about the prescription of statins to patients with 
unexplained persistent elevation of liver enzymes or active liver disease. Hence, 
randomized clinical trials of suitable sample size and duration are needed.  
Ezetimibe (EZ), another lipid-lowering drug, inhibits cholesterol absorption by 
selectively binding to the cholesterol transporter NPC1L1 at both hepatocytes 
and enterocytes [133, 134]. It is mainly used as a secondary therapy to statins to 
further reduce LDL-C. EZ has recently been used in the treatment of 
NAFLD/NASH and shown promise in both experimental animal models and 
small clinical trials [135-141]. It reduces insulin resistance and steatosis in both 
rats and mice [136-138]. In a non-obese population, a 6-month treatment of EZ 
reduced plasma alanine aminotransferase (ALT) and cholesterol by 40% and 
10%, respectively [141]. In another 6-month open label, pilot study, EZ 
significantly improved liver histology and other markers of liver disease 
including serum ALT, aspartate aminotransferase (AST), and γ-glutamyl 
transpeptidase [139]. In the largest clinical study to date (n=45) in a Japanese 
population, EZ reduced ALT at 12 months and resulted in modest, but 
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significant reductions in steatosis, ballooning, and other indices of NAFLD by 24 
months [135]. The mechanism by which EZ is thought to provide benefit in 
NAFLD is not fully understood but may be due to the reduced flux of cholesterol 
from the intestine to liver, thereby reducing the inflow of cholesterol to 
hepatocytes [142]. Currently, EZ monotherapy is not indicated in the treatment 
of NAFLD and large controlled clinical trials are needed to confirm its 
effectiveness in patients with NAFLD/NASH. 
Although reducing plasma LDL-C levels by using lipid-lowering drugs 
significantly decreases total mortality from CVD, the protection is not complete 
[143]. In a large proportion of patients, even though LDL-C is intensively 
reduced with statin therapy, low HDL-C still promotes the progression of 
disease [143-146]. An emerging body of work suggests that the flux of cholesterol 
through lipoproteins is more relevant to CVD than their absolute levels in 
plasma. Consequently, there has been intensely increased interest in strategies 
aimed at enhancing cholesterol efflux from peripheral tissues and promoting its 
transport to the liver for excretion.  
Reverse cholesterol transport (RCT): Current and future directions 
The most widely accepted strategy to enhance sterol flux from peripheral tissues 
to liver for ultimate excretion into feces is through the acceleration of a process 
termed reverse cholesterol transport (RCT). HDL is the predominant cholesterol 
acceptor and carrier in RCT. Both liver (70%) and intestine (30%) synthesize the 
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principal protein component of HDL, apoAI, and release it as a lipid-free pre- 
HDL particle to acquire FC exported by ABCA1 from peripheral cells such as 
macrophages [147]. The FC in nascent HDL, as it travels through circulation, is 
subsequently converted to cholesteryl ester by lecithin-cholesterol 
acyltransferase (LCAT), generating a mature form of HDL. The mature HDL then 
transports cholesterol back to the liver for excretion into the bile either as FC or 
bile salts. The uptake of cholesteryl ester from HDL is mediated by a membrane 
protein on hepatocytes, scavenger receptor class B member 1 (SR-BI). SR-BI is 
actively involved in the selective cholesterol uptake and trans-hepatic cholesterol 
elimination. In humans, due to the activity of plasma cholesteryl ester transfer 
protein (CETP), HDL can transfer cholesterol to VLDL and LDL via the 
remodeling action of CETP and eventually deliver cholesterol back to liver 
through LDLR-mediated endocytosis. However, in mice, a species that lacks 
CETP activity, the predominant lipoprotein in RCT is HDL.  
A substantial amount of work has been devoted to the conceptual approaches to 
augment RCT by improving cellular cholesterol efflux from peripheral cells, 
enhancing the functionality of circulating HDL, and increasing hepatic uptake of 
returned cholesterol. Relatively little effort has been geared at developing 
therapeutic approaches to target the final step of RCT.  
ABCG5 ABCG8 (G5G8) in accelerating RCT 
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The terminal hepatic and intestinal components of RCT are often overlooked due 
to their relatively less contribution to the anti-atherosclerotic effect of RCT. 
However, as the discovery of several transporters involved in the final step of 
RCT, there is nevertheless substantial interest in understanding the mechanisms 
that regulate the excretion of cholesterol into bile. Recent studies suggest that 
cholesterol taken up by hepatocytes is secreted into bile via the apical membrane 
sterol transporters ABCG5 and ABCG8 (G5G8) [2-4]. 
ABCG5 (G5) and ABCG8 (G8) are two independent ABC half transporters. They 
are located on chromosome 2P21 adjacent to each other in a head-to-head 
orientation separated by a short intergenic region [148]. This shared intergenic 
promoter contains response elements for a variety of transcriptional factors 
including liver X receptors (LXR) α and β, hepatocyte nuclear receptor 4α 
(HNF4α), GATA transcription factors, orphan nuclear receptor liver receptor 
homolog-1 (LRH-1), thyroid hormone receptor, and FOXO1[149-153]. It also 
ensures the simultaneous expression of both G5 and G8, which is required for the 
heterodimeric protein complex formation and trafficking to the cell surface [154, 
155]. 
The G5G8 heterodimer is formed in the ER in an N-linked glycan dependent 
manner facilitated by the lectin chaperones calnexin and calreticulin [156, 157]. 
Upon formation, it travels through Golgi apparatus and is predominantly 
expressed at the apical surface of hepatocytes in the liver and enterocytes in the 
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small intestine. Overexpression of calreticulin increases the abundance of the 
G5G8 complex at the cell surface, indicating that protein folding and G5G8 
complex formation is a limiting factor that determines G5G8 abundance and 
activity [156].  
G5G8 is the primary mediator of hepatobiliary elimination, accounting for 70% to 
90% of biliary cholesterol secretion [152]. This process requires bile salt micelles 
to effectively mediate cholesterol efflux[158]. In addition, G5G8 also opposes 
phytosterol absorption in the small intestine [148, 152].  
Phytosterols are plant-derived compounds that naturally exist in diet. They share 
an identical ring structure with cholesterol, but differ in the side chain. Both 
cholesterol and phytosterols can be absorbed by NPC1L1 in the small intestine. 
Unlike cholesterol, phytosterols are not suitable substrates for the acetyl-CoA 
acetyltransferease 2 (ACAT2) and hence are not esterified in enterocytes. G5G8 
recognizes the free form of phytosterols and transports them back into the 
intestine lumen for excretion. This coordinated mechanism of G5G8 and ACAT2 
allows the body to proficiently distinguish cholesterol from phytosterols, prevent 
excess cholesterol being absorbed, and ensure low levels of plasma phytosterols 
[159, 160]. Though dietary supplementation of phytosterols has been reported to 
lower LDL-C levels, reduce plaque formation and atherosclerosis in both 
experimental and clinical studies, their overwhelming accumulation in tissues is 
deleterious[161-163].  
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Defects in either G5 or G8 produce Sitosterolemia (OMIM, #210250), a rare 
autosomal recessive disorder characterized by roughly a 50-fold increase in 
plasma concentrations of phytosterols. Patients with Sitosterolemia usually 
present increased intestinal absorption of dietary sterols and a defect in biliary 
sterol secretion, which result in the accumulation of both cholesterol and 
phytosterols in plasma and tissues [164]. The excess accumulation of phytosterols 
contributes to the development of tendon and tuberous xanthomas, 
hypercholesterolemia, atherosclerosis, and premature coronary artery disease.  
A mouse model of Sitosterolemia has been generated and well-studied over the 
past decade, in which mice are homozygous for G5G8 mutations. G5G8 
knockout (KO) mice present strikingly reduced levels of biliary cholesterol. 
While the fractional absorption of phytosterols (e.g., sitosterol, campesterol) is 
significantly increased, that of cholesterol maintains relatively unaltered. Both 
hepatic and plasma sterols are dramatically increased due to the disrupted 
biliary secretion and increased intestinal absorptions. 
As reviewed earlier in this dissertation, obesity and insulin resistance may play a 
central role in the pathogenesis of MetS and NAFLD. ER stress and FC have also 
been recently appreciated as new suspects in the pathogenesis of 
NAFLD/NASH. There is emerging evidence that G5G8 ties the link of sterol flux 
to all these risk factors [165-167]. For example, the absence of G5G8 in mice 
challenged with a phytosterol-free, HF diet results in reduced biliary and fecal 
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cholesterol elimination, accelerated development of obesity and insulin 
resistance, increased accumulation of hepatic lipids in the form of both TG and 
FC, activated ER stress and UPR signaling, and worsening of NAFLD [165].  
Conversely, increasing biliary cholesterol secretion by adenoviral expression of 
G5G8 improves hepatic insulin signaling and restores glycemic control and TG 
metabolism in db/db mice, a heavily used mouse model of MetS and NAFLD 
[167]. These observations indicate that the protective role of G5G8-mediated 
cholesterol flux through the biliary tract promises it as a conceptual target to 
accelerate RCT. Similarly, in LDLR deficient mice, expression of a G5G8 
transgene reduces atherosclerosis, suggesting that therapeutic approaches that 
accelerate G5G8 activity may augment RCT and be beneficial in the prevention 
and treatment of CVD [168, 169]. Although G5G8 has been known to increase 
cholesterol excretion for over a decade, there has been little interest and progress 
in drug development for this target due to that several concerns have not been 
addressed. 
First of all, to develop such an approach, the knowledge of molecular mechanism 
responsible for the regulation of G5G8 function is indispensable. Though the 
main steps involved in G5G8 transcriptional regulation have been elucidated, 
little is known about the mechanisms responsible for the post-transcriptional 
control of G5G8. Both ob/ob and db/db mice present multiple features of MetS and 
NAFLD, such as obesity, insulin resistance, hyperglycemia and 
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hypertriglyceridemia. However, they are paradoxically resistant to the formation 
of cholesterol gallstones when challenged with a lithogenic diet [170]. This is in 
part due to the downregulation of hepatic G5G8 protein and a reduction in 
biliary cholesterol [166, 171-176]. The underlying mechanisms responsible for the 
reduced G5G8 protein expression in these mice may provide a clue to the 
development of effective therapy for the metabolic disease. In Chapter 2, a series 
of mouse models were used to address the potential mechanisms responsible for 
the post-transcriptional regulation of G5G8 in leptin-axis deficient mice.  
Secondly, previous studies suggest an interdependent relationship between liver 
and intestine for cholesterol elimination from the body. The beneficial effects of 
increased biliary cholesterol secretion are opposed by intestinal reabsorption, 
and similarly, the beneficial effects of blocking cholesterol absorption are 
opposed by reduced biliary secretion [167-169]. This suggests that a combination 
therapy that increases biliary cholesterol secretion and simultaneously reduces 
intestinal absorption is likely to act additively in the elimination of cholesterol 
from the body. Combination therapy is usually more effective, especially when 
complementary mechanisms of action are involved. Thus, in Chapter 3, we 
proposed a combined pharmacological approach to accelerate cholesterol 
elimination and tested its efficiency in mouse models. 
Lastly, increasing biliary cholesterol secretion is expected to raise the cholesterol 
saturation index of bile and the risk for cholesterol gallstones. Thus, a 
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pharmaceutical candidate that increases biliary cholesterol secretion but has 
beneficial effect of dissolving cholesterol gallstone would be a viable option. In 
Chapter 3, we found that ursodeoxycholic acid (UDCA), an active 
pharmaceutical ingredient of ursodiol (Urso) is such an option.  
Hepatic cholesterol catabolism: Bile acid synthesis 
G5G8-mediated biliary cholesterol secretion is a direct pathway to excrete excess 
hepatic cholesterol. An alternative pathway for the body to excrete excess 
cholesterol is through cholesterol catabolism by converting cholesterol to bile 
acids. This is exclusively completed in liver. Both of them facilitate the final step 
of RCT. 
Bile acid synthesis not only constitutes a route to consume cholesterol but also 
produces biological detergents important for producing micelles to solubilize 
dietary cholesterol, fats, and necessary nutrients. The conversion of cholesterol to 
bile acids includes both the neutral and acidic pathways initiated via the action 
of CYP7A1 and sterol 27-hydroxylase (CYP27A1), respectively [121-123]. As for 
the neutral or sometimes called the classic pathway, CYP7A1 is the rate-limiting 
enzyme that controls the hydroxylation of cholesterol to 7α-hydroxycholesterol 
[177, 178]. Another critical enzyme that catalyzes the subsequent reaction is sterol 
12-alpha-hydroxylase (CYP8B1). For acidic pathway, the bile acid intermediates 
produced by sterol 27-hydroxylase (CYP27A1) are then participating in the 
reaction catalyzed by 25-hydroxycholesterol 7-alpha-hydroxylase (CYP7B1).  
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Bile acids are conjugated either with glycine or taurine to yield the glycol- or 
tauro-conjugates, respectively. The bile salt export protein (BSEP; ATP-binding 
cassette B11, ABCB11) subsequently transports the glycine or taurine conjugates 
of bile acids into bile. Once bile salts are secreted into intestinal lumen, the 
majority of them (~95%) are reabsorbed via the apical sodium-dependent bile 
transporter (ASBT) into ileal enterocytes. The ileal bile acid-binding protein 
(IBABP) then transports them across the enterocyte cytosol to the basolateral side, 
where bile salts are fluxed into the circulation via the heterodimeric organic 
solute transporter OSTα/OSTβ and eventually returned to hepatocytes by means 
of the sodium sodium (Na+)-taurocholate cotransporting polypeptide (NTCP) 
and the organic anion transporters (OATP). The overall whole cycle is termed the 
enterohepatic recirculation. This recycling mechanism plays an essential role in 
maintaining the circulation pool of bile acids, normal bile flow, thereby 
maintaining the bile acid and cholesterol homeostasis.  
Bile acid homeostasis must be tightly regulated due to the intrinsic toxic feature 
of bile acids. The most widely-studied transcriptional regulator of bile acid 
homeostasis is the farnesoid X receptor (FXR) which is highly expressed in liver 
and intestine [179]. It potently suppresses CYP7A1 through two interrelated 
mechanisms. One is that FXR induces the expression of small heterodimer 
partner (SHP), a transcriptional co-repressor that interacts with two other nuclear 
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receptors: LRH-1 and HNF4α and indirectly binds to the CYP7A1 promotor and 
suppresses its transcription [180-182].  
The other mechanism is through the regulation of fibroblast growth factor (FGF) 
15/19. FGF19 and FGF15 share 53% amino acid identity with each other. FGF19 
in humans has similar tissue expression patterns, physiological functions, and 
pharmacological effects as FGF15 in mice [183-185]. There is definitive evidence 
that FGF15 and FGF19 are orthologous proteins. Hence, we refer to the hormone 
collectively as FGF15/19 unless referring to a specific ortholog. Unlike other 
FGFs that act in an autocrine or paracrine fashion, FGF15/19 has reduced 
heparin affinity that permits it to act as an endocrine hormone. FGF15/19 is 
predominately expressed in the ileum and controlled by FXR. When bile acids 
are (re)absorbed from the intestinal lumen, they act on the FXR/RXR 
heterodimer to induce FGF15/19 expression. The secreted FGF15/19 travels in 
circulation but fails to activate FGF receptors (FGFRs) on its own in liver due to 
the reduced affinity and interaction between FGFs and their receptors. It requires 
the assistant of β-Klotho, a transmembrane protein, which enables the binding of 
FGF15/19 to FGFR4 and functions as a co-receptor to initiate the FGF15/19-
FGFR4 signaling and repress CYP7A1 in liver. It has been reported that in SHP 
KO mice, the FGF15/19-mediated suppression of CYP7A1 is lost [186]. This 
demonstrates that FGF15/19-FGFR4-β-Klotho signaling pathway and the SHP 
repression pathway converges in mediating CYP7A1 transcription.  
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In Chapter 3, we observed that UDCA stimulated the ileal expression of FGF15, 
suppressed CYP7A1 expression, and increased hepatic G5G8 protein expression. 
This underlines FGF15/19 as a post-transcriptional mechanism for G5G8 
regulation. In Chapter 4, seeking evidence in support of this hypothesis, we 
tested the ileal FGF15 in LIRKO mice, which expressed higher levels of G5G8 
protein, as well as the hepatic G5G8 protein expression in Asbt KO mice, which 
had suppressed ileal FGF15 expression. 
Another endocrine action of FGF15/19 in bile acid regulation is to promote 
gallbladder filling at least in part by causing a cyclic adenosine monophosphate 
(cAMP)-dependent relaxation of gallbladder smooth muscle [187]. FGF15-KO, 
FGFR4-KO, and β-Klotho-KO mice all have small or even virtually empty 
gallbladders, while administration of recombinant FGF19 into FGF15-KO mice 
results in a rapid gallbladder filling [187-189]. Interestingly, it has been newly 
discovered that cAMP signaling machinery is responsible for the accelerated 
trafficking of G5G8 to the bile canalicular membrane in response to nutrient 
loading [190]. This further supports that FGF15/19 may be a regulator of G5G8 
and it regulates G5G8 probably through the cAMP signaling. Unraveling the role 
of FGF15/19 in the regulation of G5G8 may provide an alternative strategy in 
drug development to target G5G8 activity and the final step of RCT.  
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CHAPTER 2: THE POST-TRANSCRIPTIOANL REGULATION OF ABCG5 
ABCG8 STEROL TRANSPORTER IN LEPTIN-AXIS DEFICIENT MICE 
 
INTRODUCTION 
The ABCG5 ABCG8 locus encodes a pair of ABC half transporters that form a 
G5G8 complex that promotes the secretion of cholesterol into bile and opposes 
the absorption of dietary sterols in the small intestine [191]. Mutations in either 
ABCG5 or ABCG8 cause Sitosterolemia, a recessive monogenic disorder 
characterized by elevated plasma cholesterol and plant sterols, tendon and 
tuberous xanthomas, and accelerated atherosclerosis [191]. G5G8 deficiency also 
results in reduced cholesterol elimination, exacerbated hepatic insulin resistance, 
and the development of NAFLD in a mouse model of diet-induced obesity [165]. 
Conversely, accelerated biliary cholesterol secretion through G5G8 
overexpression improves glycemic control and hepatic insulin signaling in db/db 
mice [192]. In LDLR deficient mice, expression of a G5G8 transgene reduces 
atherosclerosis, suggesting that therapeutics that accelerate G5G8 activity may be 
beneficial in the prevention and treatment of CVD [168, 169]. 
G5G8 heterodimers are formed in the ER in an N-linked glycan dependent 
manner facilitated by the lectin chaperones calnexin and calreticulin [156, 157]. 
Overexpression of calreticulin increases the abundance of the G5G8 complex at 
the cell surface, indicating that protein folding and G5G8 complex formation is a 
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limiting factor that determines G5G8 abundance and activity [156]. G5G8 
complex formation and trafficking to the cell surface requires simultaneous 
expression of both G5 and G8 [154, 155], which is accomplished by a common 
promoter containing response elements for a number of transcription factors 
including LXR α and β, HNF4α, GATA transcription factors, LRH-1, thyroid 
hormone receptor, and FOXO1 [149-153]. The upregulation of G5G8 by FOXO1 is 
clinically significant because it mechanistically ties an increased risk for 
cholesterol gallstones to a hepatic insulin resistance [193]. Additionally, 
quantitative trait locus mapping has identified Abcg5Abcg8 as a lithogenic locus 
in mice, and polymorphisms in both ABCG5 and ABCG8 have been associated 
with increased risk of cholesterol gallstones in humans [194].  
Mice lacking leptin (ob/ob) or its receptor (db/db) are obese and insulin resistant, 
but are paradoxically resistant to the formation of cholesterol gallstones when 
challenged with a lithogenic diet [170]. Multiple mechanisms appear to 
contribute to this phenotype, including a downregulation of hepatic G5G8 and a 
reduction in biliary cholesterol [166, 171-176]. Leptin replacement in ob/ob mice 
increases hepatic G5G8 and cholesterol concentrations in gallbladder bile, 
suggesting that leptin may directly regulate G5G8 abundance and activity [166, 
175]. However, in the present study, leptin administration in ob/ob mice failed to 
acutely increase hepatic G5G8. In addition, hepatic branch vagotomy failed to 
alter G5G8 in obese mice, indicating that centrally acting leptin was not a direct 
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regulator of G5G8 abundance. Likewise, deletion of hepatic leptin receptors had 
no effect on G5G8. 
Caloric restriction can partially rescue G5G8 and biliary cholesterol 
concentrations in db/db mice, suggesting that other mechanisms secondary to 
obesity may destabilize the G5G8 complex in mice that lack a functional leptin 
axis [166, 195].  Markers of ER stress are elevated in the liver of ob/ob mice and 
are associated with the development of hepatic insulin resistance and fatty liver 
disease [96, 111]. Alleviation of ER stress through the chemical chaperones 4-PBA 
and TUDCA restores insulin signaling and glycemic control [111]. We previously 
reported that TUDCA increases G5G8 in db/db mice; however, it has a virtually 
identical effect in lean C57BL mice in the absence of ER stress [166].  
Furthermore, TUDCA stimulates bile flow and increases biliary cholesterol 
secretion in lean mice presenting no ER stress, suggesting its effects on G5G8 
may be independent of chaperone function [196, 197]. Indeed, TUDCA has a 
number of effects beyond chaperone functions, including opposing 
mitochondrial depolarization, caspase activation, and apoptosis [198-200]. 
Therefore, whether the reduction of hepatic G5G8 in ob/ob and db/db mice is a 
consequence of ER dysfunction remains unclear.   
GRP78 is an ER chaperone and component of UPR. In the face of ER stress, 
induction of GRP78 plays an essential role in promoting protein folding and 
assembly, targeting aberrant protein for degradation, and increasing the folding 
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capacity of ER. Hepatic ER stress also contributes to increased lipogenesis and 
steatosis by promoting the processing of SREBPs [112]. SREBPs are among a 
family of ER membrane proteins that traffic to the Golgi in response to metabolic 
signals and are proteolytically processed to release their respective transcription 
factor domains [39]. Exogenous expression of GRP78 by adenoviral 
administration reduces lipogenesis and steatosis by preventing the unregulated 
trafficking and activation of SREBP1-c [112]. Since ER folding capacity is a 
limiting factor in G5G8 abundance, we tested the hypothesis that adenovirus 
encoding GRP78 (AdGRP78) would restore G5G8 in db/db mice. As predicted, 
G5G8 abundance and biliary cholesterol increased following expression of 
AdGRP78. These results reveal a role for ER stress as a mechanism for reduced 
G5G8 in mice lacking a functional leptin axis.  
MATERIALS AND METHODS 
Chemicals, reagents and antibodies 
General chemicals were purchased from Sigma, immunoblotting reagents from 
Pierce, real-time PCR reagents from Applied Biosystems, mouse recombinant 
leptin from Biomyx Technology (San Diego, CA), and mouse leptin ELISA from 
EMD Millipore. Calnexin and GRP78 antibodies were purchased from Nventa 
(San Diego, CA). The α-tubulin and β-actin antibodies were purchased from Cell 
Signaling and Sigma, respectively. Anti-SR-BI was purchased from Novus. Anti-
ABCA1 antibody was a generous gift from Manson Freeman (Harvard Medical 
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School, Boston, MA). Anti-calreticulin antibody was purchased at Stressgen 
Bioreagents Corp. Total and phospho- PERK antibodies were purchased from 
Cell Signaling Technology. Experiments presented in Figure 2.1 were conducted 
with previously described antibodies directed against G5 and G8 [154, 155]. 
Stocks of the rabbit polyclonal antibody directed against G5 have become limited 
and suitable commercially available sources have not been identified. Therefore, 
we contracted ProSci Inc. (Poway, CA; NIH/OLAW assurance #A4550-01) to 
synthesize a peptide from the N-terminus of the rat ortholog of G5 
(MGELPFLSPEGARGPHINRGSLSSLEC) for antibody development in chickens. 
Antibodies were affinity purified and tested for suitability in western blotting 
and immunofluorescence microscopy applications in mouse and rat livers. The 
chicken anti-G5 polyclonal antibody was used for experiments presented in 
Figures 2.3, 2.4, 2.6, 2.7, and 2.8. 
Animal husbandry 
Male mice lacking functional leptin (ob/ob, stock #000632), and the leptin 
receptor (db/db, stock #000697) on the C57BL/6J background and their lean 
littermate controls were purchased from The Jackson Laboratory (Bar Harbor, 
ME). Upon arrival mice were allowed to acclimatize for a period of 7 days prior 
to initiation of studies. Mice harboring two copies of the floxed leptin receptor 
allele (ObRf/f) were provided by Dr. Jeffrey Friedman (The Rockefeller 
University) and maintained in our colony [201]. Animals were housed in 
individually ventilated cages in a temperature-controlled room with a 14:10 light: 
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dark cycle and provided with enrichment in the form of acrylic huts and nesting 
material. All mice were maintained on standard rodent chow (Harlan Teklad 
2014S).  
Leptin treatment 
Mice lacking leptin (ob/ob, n=3) were injected (i.p.) with either saline or 10 
mg/kg mouse recombinant leptin within 30 min of “lights-on” at 06:00. All mice 
were placed in clean cages with full access to water, but without food. Blood and 
tissues were collected 4, 8, and 16 h following leptin administration. For the 16 h 
time-point, a second injection of leptin was administered at 8 h. Blood leptin 
levels were determined at the time of tissue collection by ELISA. 
Adenoviral mediated hepatic gene expression 
AdGRP78 and a control virus (AdEmpty) were previously reported [112]. 
Adenovirus encoding Cre-recombinase (AdCre) was purchased from Microbix 
Biosystems, Inc. (Mississauga, Ontario, Canada). AdCre, AdGRP78, and 
AdEmpty were amplified in HEK293Q cells and purified on cesium chloride 
gradients as previously described [154]. Purified adenovirus was diluted in 
sterile saline and mice (8-12 weeks) were injected through the tail vein with 
4x1012 particles/kg body weight. Analysis of AdCre injected ObRf/f and wild-
type (ObRWT) mice were conducted two weeks following viral delivery. Analysis 
of control and GRP78 expressing mice was conducted five days following 
infection. 
Immunoblot and Quantitative Real-time PCR 
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Total membrane preparations from liver samples were prepared and proteins 
analyzed by SDS-PAGE (50 μg/lane) and immunoblotting as previously 
described [166]. The signals were quantified by densitometry using ImageJ 
software. Total RNAs were extracted from liver tissue using RNA STAT-60 (Tel-
Test, Inc) and subjected to cDNA synthesis with iScript cDNA Synthesis Kit 
(BIO-RAD, Hercules, CA). To determine relative abundance of transcripts, RT-
PCR was conducted using SYBRGreen as detector on Applied Biosystem 7900HT 
fast-Real Time PCR System (Carlsbad, CA) [165]. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as an internal control for the normalization 
of data in all RT-PCR experiments.  
Plasma and biliary lipid analysis 
Plasma TG concentrations were determined enzymatically using the L-type TG 
M kit. Biliary cholesterol concentrations were determined using the cholesterol E 
kit (Wako Chemicals, Richmond, VA). 
Statistical Analysis 
All statistical analyses were conducted using GraphPad Prism. Data are 
expressed as mean ± SEM. Data were analyzed by two-tailed t-test, one-way 
ANOVA, or two-way ANOVA as indicated in figure legends. Post-hoc 
comparisons were conducted by using Dunnett’s tests for one-way ANOVA and 
Bonferroni post-tests for two-way ANOVA, respectively. Differences were 
considered significant at P < 0.05. 
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RESULTS 
To determine if leptin could acutely increase hepatic G5G8 abundance, we chose 
a 10 mg/kg dose that we previously reported to restore hepatic G5G8 in ob/ob 
mice following seven days of treatment [166]. To ensure that this dose was 
biologically active over the course of our study, we monitored food intake for 
three consecutive days prior to, and following, a single dose of leptin (Fig 2.1A). 
Leptin administration immediately suppressed food intake to levels generally 
observed in wild-type (WT) mice over the first 24 h, indicating that leptin was 
centrally active over the course of our experiment. Interestingly, food intake 
remained significantly suppressed for at least seven days following this single 
dose.  
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Figure 2.1. Leptin acutely suppresses food intake, but fails to restore hepatic 
G5G8 in ob/ob mice. (A) Food intake was monitored for three consecutive days 
in ob/ob mice (n=4). A single dose of leptin (10 mg/kg, ip) was administered 
(Day 0) and food intake monitored for seven additional days. Intake following 
leptin treatment was compared to the three-day pre-treatment mean by one-way 
ANOVA. A Dunnett’s test was used to determine differences from the three-day 
pre-treatment mean (a, p<0.01; b, p<0.05). (B-D) In a second cohort of lean and 
ob/ob mice (n=3), tissues were harvested at 4, 8, and 16 h following the initial 
injection of either saline or leptin. (B) Serum leptin levels at the time of tissue 
collection were determined by ELISA. (C-D) Relative protein abundance was 
determined by densitometry using ImageJ software after normalization to 
calnexin (CNX). Data are mean ± SEM and were analyzed by one-way ANOVA. 
Post-hoc comparisons were conducted using Dunnett’s tests ** p<0.01, 
***p<0.001. 
 
Ob/ob mice were injected with saline or leptin and tissues collected 4, 8, and 16 h 
after administration. For the 16 h time-point, a second injection of leptin was 
administered at 8 h. Blood leptin levels were determined by ELISA at the 
termination of the experiment (Fig 2.1B). Lean control mice had leptin levels of 
1.5 ng/ml, while levels in saline treated ob/ob mice were at the lower limit of 
detection in our assay. Serum leptin in ob/ob mice injected with leptin was 30 
ng/ml at 4 h and declined to 8 ng/ml by 8 h, but increased to 20 ng/ml at 16 h 
following the second injection. While these levels of leptin were substantially 
higher than lean controls, they are typical of obese mice maintained on HF diets 
[202]. Hepatic levels of G5 and G8 were analyzed by immunoblotting (Fig 2.2). 
Densitometric analysis of immunoblots of hepatic G5 and G8 confirmed that G5 
and G8 protein levels were low in ob/ob mice compared to lean littermates (Fig 
2.1C, D). Administration of leptin failed to increase G5 or G8 at 4, 8, or 16 h 
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following the initial injection, indicating that centrally acting leptin had no 
immediate impact on hepatic G5G8 protein. 
 
 
Figure 2.2 G5/G8 protein expression in liver tissues of ob/ob mice and their 
lean controls. Liver tissues of lean and ob/ob mice (n=3) were harvested at 4, 8, 
and 16 h following the initial injection of either saline or leptin. Hepatic levels of 
G5 and G8 were analyzed by immunoblotting. Membrane proteins were also 
blotted for calnexin (CNX) as controls for equal protein loading. 
 
 
As an alternative approach to hormone replacement, hepatic G5G8 was 
examined in obese mice that had undergone hepatic vagotomy to determine if 
vagal mediated effects of chronic, centrally-acting leptin could regulate G5G8 
abundance. Hepatic vagotomy was performed in anesthetized 8-week-old male 
mice on the C57BL/6 background as previously described [203]. Mice were 
allowed to recover, maintained on standard chow diet for one week after 
vagotomy, and then switched to HF diet (Bio-Serv, #F3282) feeding for 10 weeks. 
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At termination, liver tissues were harvested and hepatic levels of G5 and G8 
analyzed by immunoblotting (Fig 2.3). Neither G5 nor G8 protein levels were 
affected by hepatic branch vagotomy, indicating that centrally acting leptin failed 
to regulate hepatic G5G8 via vagal innervation in obese mice.  
 
Figure 2.3 Hepatic branch vagotomy fails to alter the abundance of G5G8 in 
the setting of obesity. Liver tissues of obese mice that had undergone hepatic 
vagotomy (HV) and their sham-operated controls (n = 3) were harvested after 
being maintained on high fat feeding for 10 weeks. (A) Hepatic levels of G5 and 
G8 were analyzed by immunoblotting. (B) Relative protein abundance was 
determined by densitometry using ImageJ software after normalization to β-
actin. Data are mean ± SEM. Differences were determined by two-tailed t-test. 
 
 
Although expression of the long, signaling form of the leptin receptor is low in 
peripheral tissues, a number of studies indicate functions for peripheral leptin 
receptor isoforms [204, 205]. Hepatic leptin receptors from mice harboring floxed 
leptin receptor alleles (ObRf/f) were selectively depleted with AdCre. WT and 
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ObRf/f mice were injected with AdCre and analyzed 2 weeks following treatment 
(Fig 2.4). Commercially available antibodies for leptin receptor proved 
unsatisfactory for hepatic protein level determination. An RT-PCR assay 
detecting all ObR isoforms demonstrated a 70% reduction in hepatic mRNA 
levels (Fig 2.4A). Food intake was not affected over this period and there were no 
differences in body weight (data not shown). Neither G5 nor G8 mRNA or 
protein levels were affected by depletion of hepatic leptin receptors (Fig 2.4A, B). 
Similarly, no changes were observed in biliary cholesterol concentrations (Fig 
2.4C). These results failed to support direct effects of centrally or peripherally 
acting leptin on G5G8 abundance.  
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Figure 2.4 Depletion of hepatic leptin receptors does not reduce G5G8. An 
adenoviral vector encoding Cre recombinase (AdCre) was administered to WT (n 
= 3) and mice harboring two floxed alleles for leptin receptor (ObRf/f, n = 3). (A) 
Hepatic levels of leptin receptor (ObR), G5 and G8 mRNA were quantified by 
RT-PCR. (B) The abundance of hepatic G5 and G8 protein was determined by 
immunoblotting. (C) Biliary cholesterol concentrations were determined by 
colorimetric-enzymatic assay. Data are mean ± SEM. Differences were 
determined by two-tailed t-test ***p<0.001. 
 
 
Expression of the ER chaperone protein GRP78 has been shown to alleviate 
markers of ER stress and reverse key features of the fatty liver phenotype in ob/ob 
mice [112]. The formation and trafficking of the G5G8 heterodimer is critically 
dependent upon the ER calnexin/calreticulin chaperone system. Therefore, we 
tested the hypothesis that elevated expression of GRP78 could restore G5G8 in 
db/db mice. A small cohort of lean mice (n = 3) was also administered AdEmpty 
and AdGRP78 as an additional control. Tissues were harvested 5 days following 
viral administration. AdGRP78 increased hepatic GRP78 compared to mice 
infected with the control virus (Fig 2.5A). Immunoblot analysis demonstrated a 
reduction in phospho-PERK following GRP78 expression, indicating a reduction 
in UPR signaling (Fig 2.5A, B). As previously published in ob/ob mice, expression 
of AdGRP78 reduced expression of SREBP1-c, as well as its target genes 
acetylCoA carboxylase 1 (ACC1) and fatty acid synthase (FAS), in the lipogenic 
pathway (Fig 2.5C). Similarly, plasma TGs and liver to body weight ratios were 
elevated in obese, db/db mice and reduced by elevated GRP78 expression to levels 
observed in lean controls (Fig 2.5D, E). These data confirmed the primary 
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observations previously made in ob/ob mice and extended them to the db/db 
model.  
 
Figure 2.5 AdGRP78 alleviates ER stress, reduces lipogenic gene expression, 
and normalizes plasma TGs and liver weight in db/db mice. Control 
(AdEmpty) and GRP78 (AdGRP78) adenoviral vectors were administered to lean 
(n = 3) and db/db (n = 5 WT and 6 KO) mice. Tissues were harvested for analysis 
5 days following viral expression. (A) GRP78, total and phosphorylated (P-) 
PERK in db/db mice were assessed in hepatic lysates by SDS-PAGE and 
immunoblotting. α-tubulin was used as a loading control. (B) The ratio of 
phosphorylated to total PERK was determined by desitometry using ImageJ. (C) 
The mRNA for lipogenic genes SREBP1-c, acetylCoA carboxylase 1 (ACC1), and 
fatty acid synthase (FAS) was determined by RT-PCR. (D) Plasma TGs and (E) 
liver weight to body weight ratio (LW/BW) were determined in both lean and 
db/db mice. Data are mean ± SEM and were analyzed by two-tailed t-test (B-C) 
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and two-way ANOVA followed by Bonferroni post-tests (D-E) ** p<0.01, 
***p<0.001, ****p<0.0001. 
 
As previously reported in both ob/ob and db/db mice, hepatic G5 protein 
expression was reduced in db/db mice compared with their lean controls (Fig 2.6). 
No difference was observed in the expression of GRP78, calnexin, or calreticulin.  
 
Figure 2.6 Hepatic expression of G5, GRP78, calnexin, and calreticulin in db/db 
mice and their lean controls was determined by immunoblot analysis. 
 
 
In db/db mice, AdGRP78 increased G5 and G8 by 2.2 and 2.4 fold, respectively. 
The increase in G5 and G8 protein occurred in the absence of an increase in 
mRNA encoding either protein, consistent with a mechanism of increased 
efficiency of G5G8 complex formation within the ER (Fig 2.7A, B). An increase in 
protein expression of the ER chaperone calnexin was observed in the absence of 
an increase at its mRNA level (Fig 2.7A, B). Total cholesterol content in 
gallbladder bile was elevated most likely due to increased G5G8 (Fig 2.7C). We 
also observed significant, albeit modest, increases in both mRNA and protein 
expression of SR-BI, which is another contributor to biliary cholesterol secretion 
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(Fig 2.7A, B) [197, 206, 207]. However, there was no direct relationship between 
SR-BI and G5G8 abundance as shown in SR-BI deficient mice (Fig 2.8).  Protein 
expression of ABCA1 also increased in db/db mice following AdGRP78 treatment 
(Fig 2.7A).  
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Figure 2.7 AdGRP78 increases G5G8 at the protein level and elevates biliary 
cholesterol in db/db mice. (A) Immunoblot analysis of hepatic G5, G8, calnexin, 
SR-BI, and ABCA1. Data were analyzed by densitometry and normalized to α-
tubulin. (B) Levels of G5, G8, calnexin, and SR-BI mRNA were determined by 
RT-PCR.  (C) Total biliary cholesterol was determined by colorimetric-enzymatic 
assays. Data are mean ± SEM (n=5 WT and 6 KO). Differences were determined 
by two-tailed t-test ** p<0.01, ***p<0.001, ****p<0.0001. 
 
 
 
 
Figure 2.8 SR-BI deficiency does not directly affect hepatic G5G8. Liver tissues 
of SR-BI KO mice and their WT littermates were harvested. (A) Hepatic levels of 
G5 and G8 were analyzed by immunoblotting. (B) Relative protein abundance 
was determined by densitometry after normalization to β-actin. 
 
 
DISCUSSION 
The key finding of the present study is that expression of the ER chaperone, 
GRP78, restores hepatic G5G8 in db/db mice, whereas there is no apparent direct 
central or peripheral effect of leptin signaling on the complex. In the context of 
previously published studies that established a role for biliary cholesterol 
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secretion in opposing ER stress, the present study suggests a reciprocal 
relationship between ER function and G5G8-mediated biliary cholesterol 
secretion.  
Leptin signaling 
Leptin replacement reduces food intake and induces weight loss in ob/ob mice. 
Therefore, it is difficult to establish which effects are truly dependent upon 
central or peripheral leptin signaling or are secondary to changes in energy 
balance. We previously reported the restoration of G5G8 in ob/ob mice following 
long-term leptin replacement [166]. While an increase in immunoreactive G5G8 
was observed in pair-fed controls, leptin replacement resulted in a far greater 
increase, suggesting a direct role for leptin signaling as a regulator of hepatic 
G5G8 abundance. In the present study, leptin administration failed to acutely 
increase G5G8 after 4, 8, or 16 h when plasma levels of leptin were more than 
sufficient to mediate the central effects of this hormone. The absence of an effect 
over this period fails to support a role for centrally acting leptin on hepatic G5G8 
abundance. While it is possible that centrally acting leptin may take a greater 
period of time to restore hepatic G5G8, the abundance of G5 and G8 mRNAs 
increase after a 24 h fast in a peroxisome proliferator-activated receptor alpha 
(PPAR)-dependent fashion [195]. Consequently, observations at later time-
points would be confounded by induction of the PPAR-mediated fasting 
response. 
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Long-term stimulation of the hepatic branch of the vagus nerve reduces body 
weight and fat mass in rats [208]. Although effects of leptin in liver have been 
shown to be mediated by vagal stimulation or by hepatic leptin receptors, neither 
pathway appears to regulate hepatic G5G8 abundance [209, 210]. In our studies, 
mice that had undergone hepatic branch vagotomy failed to show any difference 
in hepatic levels of G5G8 compared with their sham-operated controls. Similarly, 
depletion of hepatic leptin receptors also failed to reduce G5G8. While these 
results support a hepatic leptin receptor-independent mechanism for reduced 
G5G8 in db/db and ob/ob mice, this experiment was limited by incomplete ObR 
depletion at the mRNA level and that hepatic leptin receptor depletion could not 
be confirmed at the protein level. 
 
Restoration of G5G8 by AdGRP78 in db/db mice 
The increase in G5G8 following AdGRP78 treatment was consistent with a 
mechanism that includes the improvement of ER folding capacity and greater 
efficiency of G5G8 complex formation within the ER. When expressed 
individually in cells, G5 and G8 have short half-lives and are rapidly degraded 
[155]. Co-expression allows for the formation of G5G8 heterodimers through a 
process that is dependent on the presence of their N-linked glycans and 
interactions with calnexin [157]. In cultured cells, co-expression of either calnexin 
or calreticulin with G5 and G8 increases the appearance of G5G8 at the cell 
surface [156]. It is important to note that GRP78 does not bind either G5 or G8 
57 
 
[157]. Therefore, it is unlikely to directly facilitate G5G8 folding. An increase in 
calnexin was also observed and is more likely to account for G5G8 rescue in db/db 
mice (Fig 5A). However, whether the increase in calnexin is required for the 
effect of GRP78 on G5G8 abundance is unknown. Apart from increased G5G8 
complex formation in the ER, other mechanisms that may account for increased 
G5G8 levels include an increase in the rates of translation for each monomer or 
increased stability of the mature, post-Golgi complex. While these alternate 
explanations have not been formally explored, the parallel increase in the 
immature and mature forms of G5 and G8 suggest that post-Golgi complex 
stability was not altered as this would result in selective accumulation of the 
mature form of each protein.  
 
ER function and G5G8 
ER stress is thought to play a causative role in the development of liver 
dysfunction in mice lacking leptin or its receptor and may directly contribute to 
the reduction in G5G8 in db/db mice. However, markers of ER stress are also 
induced in mice following high fat feeding and G5G8 levels are unaffected or 
even increased depending on the lipid composition of the diet [211-213]. While 
these observations were suggestive of a direct effect of leptin signaling on G5G8 
abundance, direct effects of leptin could not be demonstrated.  The reduction in 
G5G8 associated with ER stress in ob/ob and db/db mice may simply be a matter of 
degree. The extent of obesity, steatosis, insulin resistance, and ER dysfunction is 
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generally greater in these mice compared those with an intact leptin axis and 
challenged with various high fat diets. Alternatively, the lack of reduction in 
G5G8 protein in other models may reflect a compensatory increase in G5G8 
transcription that overcomes reduced efficiency of complex formation within the 
ER. In addition, we previously reported that other glycoproteins, including the 
closely related family member ABCG2, were not affected in mice harboring 
defects in leptin or its receptor [166]. Rescue of the complex by AdGRP78 
implicates ER dysfunction as a mechanism contributing to reduced G5G8, but 
what accounts for the selective depletion of G5G8 in db/db and ob/ob mice remains 
unknown. Perhaps G5G8 assembly is particularly sensitive to ER dysfunction. 
Alternatively, there may be some synergistic effect of the absence of leptin 
signaling and fatty liver phenotype on G5G8 abundance.     
We previously reported that the loss of G5G8 increased markers of ER stress in 
HF-fed mice, establishing that biliary cholesterol secretion is essential to 
maintain hepatocyte function [165]. Excess unesterified cellular cholesterol is 
known to induce ER stress in a number of cell types, including hepatocytes [124, 
214, 215]. Conversely, ER stress reduces ABCA1 and SR-BI and impairs 
cholesterol efflux in cultured hepatocytes [216]. Similar to G5G8, AdGRP78 
increased ABCA1 and SR-BI in db/db mice, suggesting that ER dysfunction 
perturbs multiple facets of hepatic sterol metabolism in db/db mice.  Collectively, 
the data support a reciprocal relationship between ER function and cholesterol 
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metabolism in which disturbances in cholesterol homeostasis contribute to ER 
stress and ER stress contributes to disruptions in cellular cholesterol metabolism.  
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CHAPTER 3. THE COMBINATION OF EZETIMIBE AND URSODIOL 
PROMOTES FECAL STEROL EXCRETION AND REVEALS A G5G8-
INDEPENDENT PATHWAY FOR CHOLESTEROL ELIMINATION 
 
INTRODUCTION 
Elevated cholesterol is an important risk factor for CVD and strategies to 
promote cholesterol elimination have long been employed to reduce the risk of 
atherosclerosis. An emerging body of literature suggests that cholesterol also 
plays an active role in the development of NAFLD and its progression to NASH. 
Adding cholesterol to a HF diet in C57BL/6J mice leads to significantly more 
profound hepatosteatosis, inflammation, and fibrosis resembling human NASH 
[117]. Similarly, in LDLR deficient mice, adding cholesterol to a HF, high-sucrose 
diet exacerbates the development of insulin resistance and steatosis resulting in 
NASH [118]. In a mouse model of Alström syndrome (Alms1 mutant or foz/foz 
mice), an elevation in hepatic FC due to an increase in hepatic uptake and a 
decrease in biliary elimination is thought to play a contributing role in the 
development of liver disease [124]. Strategies that promote hepatic cholesterol 
elimination are likely to have therapeutic benefit in NAFLD. 
The G5G8 heterodimer is the primary mediator of hepatobiliary elimination, 
accounting for 70% to 90% of biliary cholesterol secretion [152]. In addition, it 
also opposes phytosterol absorption in the proximal small intestine [148, 152]. 
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We previously reported that G5G8 plays an essential role in the development of 
diet-induced obesity phenotypes independent of its role in opposing phytosterol 
accumulation. The absence of G5G8 and reduced biliary cholesterol secretion 
resulted in hepatic cholesterol accumulation, acceleration of obesity and insulin 
resistance, and worsening of NAFLD in mice challenged with a plant sterol-free 
(PSF) HF diet [165]. Conversely, increasing biliary cholesterol secretion by 
adenoviral expression of G5G8 restored glycemic control, improved hepatic 
insulin signaling, and lowered plasma TGs in genetically obese, db/db mice [167].  
Increased biliary and fecal sterol elimination following adenoviral G5G8 would 
presumably lower plasma cholesterol levels in db/db mice. However, a significant 
portion of the secreted cholesterol was reabsorbed, resulting in a paradoxical 
increase in plasma cholesterol despite increased biliary output. This effect of 
adenoviral G5G8 can be overcome by co-administration of EZ, a potent inhibitor 
of cholesterol absorption that blocks NPC1L1 activity in the intestine [167, 217]. 
Similar observations were made in atherosclerosis studies in which a G5G8 
transgene expressed in both liver and intestine lowered LDL-C and reduced 
lesion area, whereas a liver specific transgene was ineffective in the absence of 
EZ [168, 169]. These observations indicate an interdependent relationship 
between biliary secretion and intestinal absorption for effective fecal cholesterol 
elimination. Consequently, therapeutic approaches to promote cholesterol 
elimination by targeting the hepatobiliary pathway are likely to be limited by 
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intestinal reabsorption of secreted cholesterol. Thus, a combination therapy that 
increases biliary cholesterol secretion and simultaneously reduces intestinal 
absorption is likely to act additively in the elimination of cholesterol from the 
body.  
While EZ is effective in reducing cholesterol absorption, no currently available 
therapeutics directly target the G5G8 sterol transporter to increase biliary 
cholesterol secretion. However, we previously published that TUDCA increases 
G5G8 and biliary cholesterol in both lean and obese, db/db mice [166]. TUDCA is 
a first pass metabolite of ursodiol (Urso). Studies in mice have shown that 
TUDCA and its unconjugated precursor, Urso, have a number of beneficial 
effects on liver function including alleviation of ER stress, improved insulin 
sensitivity and reduced lipogenesis [111, 166, 218]. However, the effect of Urso 
on increasing G5G8 and promoting biliary secretion of cholesterol has not been 
characterized.  
In the present study, we confirmed that Urso had similar effects on G5G8 as 
TUDCA. Urso increased hepatic G5G8 and dose-dependently accelerated both 
biliary and fecal sterol excretion. We then tested whether an Urso-EZ 
combination treatment would act additively to promote cholesterol elimination. 
We treated mice with a constant dose of Urso or Urso in combination with two 
doses of EZ. EZ produced an additive effect for fecal sterol excretion in the 
presence of Urso. Although biliary and fecal neutral sterols (FNS) were 
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invariably lower in G5G8 KO mice, we observed an increase in FNS following 
Urso alone or Urso-EZ combination treatments. The magnitude of this increase 
was not affected by genotype suggesting that there may be a G5G8-independent 
pathway for cholesterol elimination stimulated by Urso. 
MATERIALS AND METHODS 
Chemicals, reagents and antibodies   
General chemicals were purchased from Sigma, immunoblotting reagents from 
Thermo/Pierce, real-time PCR reagents from Applied Biosystems. 
Tauroursodeoxycholic acid, sodium salt (580549-5GM) was purchased from 
Calbiochem. Ursodiol capsules, USP (NDC 42806-503-01) were purchased from 
Epic Pharma, LLC and Zetia (ezetimibe) tablets (NDC 66582-414-54) from Merck 
& Co., Inc. Urethane, bromodeoxyuridine (BrdU), and the silylation reagent N, 
O-Bis (trimethylsilyl) trifluoroacetamide (BSTFA) were purchased from Sigma-
Aldrich. The chicken anti-G5 polyclonal antibody and the monoclonal antibody 
directed against G8 were previously reported [154, 165]. The β-actin antibody 
was purchased from Sigma. Anti-ABCA1, [26, 26, 26, 27, 27, 27-2H6] cholesterol 
and [5, 6, 22, 23-2H4] sitostanol were generous gifts from Ryan Temel (University 
of Kentucky) [219]. The anti-CD3 monoclonal antibody (clone 145-2C11) was 
purified over protein G beads (Amersham Pharmacia Biotech, Piscataway, NJ). 
Anti-BrdU was purchased from MPL International, Woburn, MA.  
EZ- and/or Urso-supplemented diets 
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Powdered rodent chow diet (T.2018M.15) was purchased from Harlan 
Laboratories. Custom formulated pellet (D10040301) and powdered 
(D10040301M) PSF diets were purchased from Research Diets, Inc. Macronutrient 
composition and sterol content were previously described [165]. There was no 
added cholesterol in the diet. Both Urso and EZ were ground into a fine powder, 
and then thoroughly mixed with control diet (T.2018M.15 or D10040301M) to 
obtain the desired concentrations. Powdered diets were provided to mice in glass 
feeding jars and replaced daily.  
Animal husbandry 
C57BL/6J (Stock #000664) mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME). Mice homozygous for the Abcg5 and Abcg8 mutant alleles 
(KO) and their WT littermates were obtained from heterozygous, trio matings as 
previously described [165]. Mice were housed in individually ventilated cages in 
a temperature-controlled room with a 14:10 light: dark cycle and provided with 
enrichment in the form of acrylic huts, wood chew sticks, and nesting material. 
Mice were adapted to powdered diet for a period of 7 days prior to initiation of 
studies. The diet was then changed to those containing various concentrations of 
Urso and EZ. All animal procedures conform to PHS policies for humane care 
and use of laboratory animals and were approved by the institutional animal 
care and use committee at the University of Kentucky. All surgery was 
performed under anesthesia, and all efforts were made to minimize suffering. 
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Animal experiments 
Male C57BL/6J mice (n=6/group) were fed chow (control), chow supplemented 
with 0.4% TUDCA (w/w), or Urso at concentrations of 0.1%, 0.3%, or 1% (w/w) 
for 7 days. Mice were housed (2 per cage) in individually ventilated cages. Mice 
were placed in clean cages to collect feces for 3 days prior to termination. On the 
final day of the study, mice were transferred to clean cages and fasted for 4 
hours. The bile duct was ligated, and the gallbladder cannulated for basal bile 
collection (30 min) under urethane (1 g/kg body weight) anesthesia. Bile flow 
was determined gravimetrically assuming a density of 1 g/ml. Mice were then 
exsanguinated, and tissues dissected, frozen in liquid nitrogen, and stored at -
80°C until analysis. Details were shown in the experimental outline for Urso 
dose-dependent study (Fig 3.1). 
 
Figure 3.1 Experimental outline for the Urso dose-dependent study. 
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Another cohort of male C57BL/6J mice (n=7) were fed chow (control), chow 
supplemented with 0.3% Urso or 0.3% Urso combined with 0.001% or 0.005% EZ 
for 14 days and were housed individually. Feces, basal bile, and other tissues 
were collected as described above (Fig 3.2).  
Figure 3.2 Experimental outline for the Urso-EZ combination study. 
 
G5G8 KO mice (n=4 both male and female) and their WT littermates (n=6 male 
and 7 female) were weaned between 18 and 21 days onto a pellet PSF diet to 
prevent the development of Sitosterolemia [165]. When maintained on this diet, 
serum levels of phytosterols are less than 10% of those observed in G5G8 KO 
mice maintained on chow diet and do not differ between genotypes (Fig 3.3). 
Prior to initiation of the study, mice were adapted to a powdered PSF (vehicle) 
diet for 7 days. Then, mice were fed a vehicle diet for 10 days (Phase I) followed 
by 0.3% Urso for 7 days (Phase II). All mice were then treated with 0.3% Urso 
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combined with 0.005% EZ for 14 days (Phase III). Feces were collected the final 3 
days of each phase. Blood samples were collected by cheek bleed at the final day 
of each phase. At termination following phase III, basal bile and tissues were 
harvested as described above (Figure 3.4). 
 
Figure 3.3 Serum levels of cholesterol and dietary phytosterols in mice 
maintained on a PSF diet. The concentrations of cholesterol and dietary 
phytosterols in G5G8 KO mice (n=3) and their WT littermates (n=3) were 
simultaneously determined by GC-MS. Serum samples from KO mice 
maintained on standard rodent chow were used as positive controls. Data are 
mean ± SEM. Differences were determined by one-way ANOVA followed by 
Bonferroni post-hoc tests. ***p<0.001, ****p<0.0001. 
 
 
Figure 3.4 Experimental outline for the G5G8-dependent study 
Another cohort of male and female G5G8 KO and WT mice (n=3 for each gender 
and genotype) treated with 0.3% Urso or a PSF vehicle diet for 7 day were used 
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to measure both fractional cholesterol absorption and intestinal epithelial cell 
sloughing as described with modifications [220, 221]. Mice were individually 
housed and adapted to a powdered PSF (vehicle) diet 7 days prior to the 
experiment in wire bottom cages. Each mouse was gavaged with 50 μl of 
deuterated sterol/stanol-oil mixture. Feces were collected for 3 days after oral 
gavage. To determine the relative rates of intestinal epithelial cell proliferation 
and turnover, each mouse was injected i.p. with 1 mg BrdU 2 hours before tissue 
dissection. Blood samples were collected, and three segments of the small 
intestine were harvested and fixed in 10% neutral buffered formalin for 
immunohistochemistry.  
Immunoblot and Quantitative Real-time PCR 
The preparations of proteins, SDS-PAGE, and immunoblotting were conducted 
as previously described [165, 167]. Total RNAs were extracted from each liver 
using the RNA STAT-60 (Tel-Test, Inc.) and subjected to cDNA synthesis with 
iScript cDNA Synthesis Kit (BIO-RAD, Hercules, CA). To determine relative 
abundance, RT-PCR was conducted using SYBRGreen detector on Applied 
Biosystem 7900HT fast-Real Time PCR System (Carlsbad, CA) [165]. 
Hepatic, serum, and biliary lipid analysis 
Hepatic lipids were extracted by using folch reagents as previously described 
[167]. Total and non-esterified hepatic and serum cholesterol, as well as 
cholesterol and phospholipids in gallbladder bile, were determined using 
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commercial colorimetric-enzymatic assays (Wako Chemicals, Richmond, VA). 
The quantitation of total bile acids in bile was performed enzymatically by 
measuring 3α-hydroxy bile acids as previously described [222]. Serum was 
fractionated by fast protein liquid chromatography (FPLC), and fractions were 
analyzed for total cholesterol content as previously described [165]. The 
concentrations of lathosterol and phytosterols in serum were measured by 
LC/MS/MS and GC-MS, respectively using modifications of previously 
published methods [2, 223-225].  
Fecal Neutral Sterols (FNS) 
FNS were analyzed as previously described with minor modifications [167]. 
Briefly, total feces from the 72-h period were collected, dried at 37 °C, weighed, 
and ground to powder. An aliquot of 0.30 g of feces was placed into a glass tube 
with 2.5 ml of ethanol and 0.5 ml of 10 N NaOH. Lipids were saponified at 72 °C 
in a water-bath for 2 h and extracted (water: ethanol: petroleum ether, 1:1:1, 
v/v/v). 0.12 mg of 5α-cholestane (1 μg/μl) was used as the internal standard. 
Following extraction, the organic phase was dried under nitrogen gas and 
solubilized in hexane. The amount of neutral sterols (cholesterol, coprostanol, 
and cholestanol) was quantified by GC-MS. 
Lathosterol Analysis 
Serum lathosterol concentrations were measured by LC/MS/MS. Lipids and 
sterols were extracted from 10 µl mouse serum by the modified Bligh/Dyer 
method [224]. D7-Lathosterol (10 µl of 100 ng/mL in methanol; Avanti Polar 
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Lipids, Alabaster, Al) was added to serum as internal standard and extracted 
sterols were converted to picolinyl esters by derivatization [225], and 
reconstituted into 300 µl acetonitrile. Lathosterol calibrators (30, 60, 100, 150, 250 
and 500 ng/ml) and quality control samples (50, 125, and 200 ng/ml) were 
prepared in the absence of serum. Processed samples were analyzed immediately 
for lathosterol content by injection (45 µl) onto a Shimadzu Prominence LC 
system coupled to an API 2000 MS/MS through an electrospray ionization 
source (+mode/5500V/500˚C/GS1 at 50/GS2 at 40). The picolinyl esters (PE) of 
D7-lathosterol and of lathosterol, were resolved from the cholesterol-PE (Rt of 
31.2, 32.0, and 34.5 min, respectively) using a Luna C18 (2)-HST analytical column 
(2.5 µ; 100x2 mm) with a guard column (C18; 4x2-mm). The isocratic mobile 
phase (0.25 mL/min) was 96:4 acetonitrile: 10 mM ammonium formate. 
Molecular ion transitions (499.4/376.5 (D7-PE) and 492.5/369.5 (lathosterol-PE) 
m/z) were monitored using voltages optimized from the individual analyte 
infusions in mobile phase. Linear regression analysis (R2=0.9985 with 1/x 
weighting) relating the mass ratios to the area ratios of lathosterol to D7-
lathosterol was performed with Analyst® software (Ver. 1.4.2). Repeated 
processing of pooled control serum indicated adequate reproducibility (avg=90.6 
ng/mL ± 2.2, RSD=2.4%, n=4) of the overall method. Standard and quality 
control samples processed alongside experimental samples, demonstrated 
accuracy of 92.7-109% of nominal values.     
Phytosterol analysis 
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Total cholesterol and phytosterol concentrations in serum were measured by GC-
MS as described with minor modifications [223]. Briefly, 20 µl of serum was 
saponified in 4% sodium hydroxyide/ethanol at 65°C for 2 h after addition of 5α-
cholestane as a quantitative internal standard. Lipids were extracted using 2 ml 
of petroleum ether and the organic fraction from each extract was removed and 
dried under nitrogen. The residual lipids were reconstituted in N, O-Bis 
(trimethylsilyl) trifluoroacetamide (BSTFA, Sigma-Aldrich) and derivatized at 
75°C for 15 min. The samples were fractionated by GC using an HP-5MS 5% 
Phenyl Methyl Siloxane column and quantified by electron ionization-MS 
operating in single-ion-monitoring mode. Each sterol was quantified using ions 
with the following m/z: cholesterol 458; campesterol 472; sitosterol 486. 
Determination of fractional cholesterol absorption 
Fractional absorption of cholesterol was measured as described with 
modifications [220]. Briefly, a mixture containing 8 mg of [26, 26, 26, 27, 27, 27-
2H6] cholesterol and 8 mg of [5, 6, 22, 23-2H4] sitostanol was prepared and 
dissolved in 4 mL of vegetable oil. A single dose of the deuterated sterol/stanol-
oil mixture (50 μl) was gavaged to each mouse. Feces were collected for 3 days 
after oral gavage, pooled, dried, and homogenized. An 80mg aliquot of stool 
from each mouse was saponfied in 4% sodium hydroxyide/ethanol at 65°C for 2 
h after addition of 80 μg of 5α-cholestane as an internal standard. Two milliliters 
of nano-pure water were added, and sterols and stanols were extracted with 2 ml 
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of hexane. Five hundred microliters of organic fraction were dried under 
nitrogen, and the residual sterols and stanols were dissolved in 400 μl of BSTFA 
and reacted at 75°C for 15 min. A 10 μl aliquot of oil mixture was extracted 
following the same procedure as fecal samples. Sterols and stanols were 
separated by GC on an HP-5MS column. Selective ion monitoring was performed 
at m/z 464 for D6-cholesterol, m/z 493 for D4-sitostanol. The fractional 
absorption of cholesterol was calculated using the following equation. 
(
[2H6]cholesterol
[2H4]sitostanol
 dose ratio −  
[2H6]cholesterol
[2H4]sitostanol
 feces ratio)
[2H6]cholesterol
[2H4]sitostanol
 dose ratio
× dose ratioanoll. Selective ion mon 
 
Determination of intestinal epithelial cell sloughing 
The jejunal epithelial cell sloughing was indirectly determined by doing a pulse 
chase experiment using Bromodeoxyuridine (BrdU) as described with 
modifications [221]. Briefly, each mouse was injected i.p. with 1mg BrdU 2 hours 
before killing. Antibodies directed against CD3 were used as positive control to 
stimulate proliferation and cell turnover. A group of 3 WT mice were injected 
with anti-CD3 18 hours before BrdU injection. Detection of nuclei that had 
incorporated BrdU was performed by immuno-histochemistry. The anti-BrdU 
antibody was diluted 1:400 in Powerblock (Dako, Carpinteria, CA). The rat IgG 
ABC kit (Vector Laboratories, Burlingame, CA) and DAB substrate chromagen 
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(DAKO) were used to develop BrdU staining. Images were acquired using an 
Olympus DP71 camera (Tokyo, Japan) and measurements were made using 
ImageJ (NIH, Bethesda, MD). Sections were analyzed by scoring 20 crypts per 
mouse, 3 mice per group. Each crypt unit was scored for BrdU positive cells. 
Villus height and crypt depth were measured as well. The slides were also 
stained with hemotoxylin and eosin (H&E) to visualize the enterocyte histology. 
The scale bar represents 50 microns for BrdU staining and 100 microns for H&E. 
Statistical Analysis 
All statistical analyses were conducted using GraphPad Prism. Data are 
expressed as mean ± SEM. Data shown in Fig 3.5-7 were analyzed by two-tailed 
t-test or one-way ANOVA followed by Dunnett’s post-hoc comparisons. Data 
shown in Fig 3.8-14 were analyzed by one-way ANOVA followed by Bonferroni 
post-hoc tests. Data shown in Fig 3.15-17 were analyzed by a two-way ANOVA 
or a repeated measure two-way ANOVA using genotype and treatment as 
factors. Post-hoc comparisons were made using Bonferroni tests. Differences 
were considered significant at P < 0.05. Where genotype and treatment by sex 
interactions were not significant, data were analyzed independent of sex.  
 
RESULTS 
Urso increases G5G8 and both biliary and FNS in a dose-dependent manner 
To determine if Urso could increase G5G8 and biliary cholesterol secretion and 
elimination, mice were fed chow (control) or chow supplemented with 0.1%, 
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0.3%, or 1% (w/w) Urso. TUDCA (0.4%, equal molar ratio to 0.3% Urso) was 
used as a positive control as it was previously shown to increase G5G8 and 
biliary cholesterol secretion. The abundance of hepatic G5 and G8 was evaluated 
by immunoblot analysis (Fig 3.5A). Urso increased hepatic G5G8 to a similar 
level at all tested doses. Its effects were equal to, or slightly greater than TUDCA, 
particularly for G8. Biliary cholesterol and FNS were used as indirect measures 
of G5G8 activity. Hepatobiliary cholesterol secretion rates under basal conditions 
were calculated from the product of bile flow and cholesterol concentration. Urso 
dose-dependently increased both biliary cholesterol secretion rates and FNS (Fig 
3.5B-C). Similarly, Urso increased biliary secretions of both phospholipids and 
bile acids in a dose-dependent manner (Fig 3.6). 
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Figure 3.5 Urso increases G5G8 and both biliary and FNS in a dose-dependent 
manner. Male C57BL/6 mice were fed with control, 0.4% TUDCA, or three doses 
of Urso for 7 days. (A) Hepatic levels of ABCG5 and ABCG8 protein expression 
were determined by immunoblotting. Membrane preparations were blotted for 
β-actin as controls. (B) Hepatobiliary cholesterol secretion rates under basal 
conditions. Gallbladder was cannulated and basal bile was collected for 30 min. 
n=6 for each group. (C) FNS was determined by GC-MS. n=3 for each group. 
Data are presented as mean ± SEM. Differences between TUDCA and control 
were determined by two-tailed t-test. Differences between control and three 
doses of Urso were determined by one-way ANOVA followed by Dunnett’s 
tests. *p<0.05, **p<0.01, ***p<0.001. 
 
 
Figure 3.6 Urso increases biliary secretion rates of phospholipids and bile 
acids. Male C57BL/6 mice were fed with control, 0.4%TUDCA, or three doses of 
Urso for 7 days. Hepatobiliary secretion rates of phospholipids (A) and bile acids 
(BAs) (B) under basal conditions. n=6 for each group. Data are presented as mean 
± SEM. Differences between TUDCA and control were determined by two-tailed 
t-test. Differences between control and three doses of Urso were determined by 
one-way ANOVA followed by Dunnett’s tests. *p<0.05, **p<0.01, ***p<0.001. 
 
Urso suppresses bile acid synthesis, but had no effect on cholesterol levels in 
liver or serum. 
Urso had no effect on either serum or hepatic total cholesterol at any of the doses 
examined (Fig 3.7A, B). To determine if the increased FNS was due to increased 
cholesterol synthesis, we measured the mRNA expression level of HMGCR and 
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HMGCS and observed no virtual differences (Fig 3.7C). To investigate the effects 
of Urso on bile acid biosynthesis, the mRNA expression level of CYP7A1, 
CYP8B1, CYP7B1, and CYP27A1 was quantified by RT-PCR (Fig 3.7D). TUDCA 
significantly decreased both CYP7A1 and CYP8B1, but not CYP7B1 and 
CYP27A1 (not shown). Similarly, both CYP7A1 and CYP8B1 decreased in a dose-
dependent manner following Urso treatment. As with TUDCA, Urso had no 
effect on CYP7B1 and CYP27A1 expression levels (not shown).  
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Figure 3.7 Urso suppresses bile acid synthesis, but had no effect on cholesterol 
levels in liver or serum. (A) Total cholesterol concentrations in serum. n=6 for 
each group. (B) Hepatic total cholesterol per gram of wet tissue weight. n=6 for 
each group. The mRNA expression for de novo cholesterol synthetic genes 
HMGCR and HMGCS (C) and bile acid synthetic genes CYP7A1 and CYP8B1 (D) 
was determined by RT-PCR. n=4-5 for each group. Data are mean ± SEM. 
Differences between TUDCA and control were determined by two-tailed t-test. 
Differences between control and three doses of Urso were determined by one-
way ANOVA followed by Dunnett’s tests. *p<0.05, **p<0.01, ***p<0.001. 
 
EZ produces an additive effect for fecal sterol elimination. 
To determine if EZ plays an additive role for accelerating cholesterol elimination, 
we treated mice with 0.3% Urso combined with two doses of EZ for 14 days. As 
with 7-day treatment, 0.3% Urso increased G5G8 protein levels in liver. This 
effect was maintained in the presence of both low- and high-doses of EZ (Fig 
3.8A). The presence of EZ had no effect on biliary secretion rates of cholesterol as 
well as phospholipids and bile acids following 2-weeks of treatment (Fig 3.8B, 
3.9). However, EZ dose-dependently increased FNS in the presence of 0.3% Urso 
(Fig 3.8C). 
78 
 
 
Figure 3.8 EZ produces an additive effect for fecal sterol elimination. Male 
C57BL/6 mice were fed with control, 0.3% Urso, or 0.3% Urso combined with a 
low or high dose of EZ for 14 days. (A) Hepatic levels of ABCG5 and ABCG8 
protein expression were determined by immunoblotting. (B) Hepatobiliary 
cholesterol secretion rates under basal conditions. n=5-7 for each group. (C) FNS 
was determined by GC-MS. n=7 for each group. Data are presented as mean ± 
SEM. Differences were determined by one-way ANOVA followed by Bonferroni 
post-hoc tests. *p<0.05, ****p<0.0001. 
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Figure 3.9 EZ has no additive effect on biliary secretion rates of phospholipids 
and bile acids. Male C57BL/6 mice were fed with control, 0.3% Urso, or 0.3% 
Urso combined with two doses of EZ for 14 days. Hepatobiliary secretion rates of 
phospholipids (A) and bile acids (BAs) (B) under basal conditions. n=5-7 for each 
group. Data are presented as mean ± SEM. Differences were determined by one-
way ANOVA followed by Bonferroni post-hoc tests. 
 
EZ reduces FC in serum, but has no additive effect on the biosynthesis of bile 
acids and cholesterol in liver. 
EZ at a concentration of 0.005% slightly reduced serum total cholesterol. This 
was predominantly due to the significant reduction of FC (Fig 3.10A). No 
differences were observed in hepatic free (not shown) or total cholesterol (Fig 
3.10B). Although there was a tendency towards suppression of cholesterol 
synthetic genes at the mRNA level, none achieved statistical significance (Fig 
3.10C). We confirmed the prominent repression of CYP7A1 and CYP8B1 at the 
mRNA level in mice treated with Urso. EZ had no additional effect on their 
mRNA levels (Fig 3.10D). This effect of Urso is likely due to the stimulation of 
ileal FGF15 which feeds back to repress hepatic bile acid synthesis (Fig 3.11). To 
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determine if extrahepatic sources might contribute to the increased FNS in 
response to Urso-EZ, we examined the mRNA expression level of HMGCR and 
HMGCS in adrenal glands, epididymal adipose tissues, and jejuna as well as the 
circulating lathosterol, an indicator of whole body cholesterol synthesis (Fig 3.12, 
13) [226]. Urso did not alter the expression level of HMGCR and HMGCS in 
tested tissues. However, the Urso-EZ combination increased HMGCS mRNA 
expression in both adrenal glands and jejuna (Fig 3.12). Circulating levels of 
lathosterol tended to increase, but did not reach statistical significance (Fig 3.13). 
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Figure 3.10 EZ reduces FC in serum, but has no additive effect on the 
biosynthesis of bile acids and cholesterol in liver. (A) Total cholesterol and 
non-esterified cholesterol (FC) were determined by Wako enzymatic-colorimetric 
kits. Cholesterol esters (CE) were calculated from the difference in total and FC. 
n=7 for each group. (B) Hepatic total cholesterol per gram of wet tissue weight. 
n=7 for each group. The mRNA expression for de novo cholesterol synthetic 
genes HMGCR and HMGCS (C) and bile acid synthetic genes CYP7A1 and 
CYP8B1 (D) was determined by RT-PCR. n=6 for each group. Data are mean ± 
SEM. Differences were determined by one-way ANOVA followed by Bonferroni 
post-hoc tests. *p<0.05, ****p<0.0001.  
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Figure 3.11 Urso decreases bile acid synthesis by stimulating ileal FGF15 
expression. The mRNA expression for ileal FGF15 (A) and FXR (B) was 
determined by RT-PCR. n=6 for each group. Data are mean ± SEM. Differences 
were determined by one-way ANOVA followed by Bonferroni post-hoc tests. 
*p<0.05, ***p<0.001. 
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Figure 3.12 EZ increases HMGCS expression in adrenal glands and jejuna. The 
mRNA expression for de novo cholesterol synthetic genes HMGCR and HMGCS 
in adrenal glands (A-B), epididymal adipose tissues (C-D), and jejuna (E-F) was 
determined by RT-PCR. n=6 for each group. Data are mean ± SEM. Differences 
were determined by one-way ANOVA followed by Bonferroni post-hoc tests. 
*p<0.05, **p<0.01.  
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Figure 3.13 EZ has no additive effect on circulating lathosterol levels. Serum 
lathosterol concentrations were determined by LC/MS/MS. Data are mean ± 
SEM. Differences were determined by one-way ANOVA followed by Bonferroni 
post-hoc tests.    
 
EZ reduces intestinal G5G8 and ABCA1. 
With recent studies characterizing trans-intestinal cholesterol excretion (TICE) as 
an alternative route for cholesterol elimination, the role of the intestine has 
regained attention [227]. G5G8 is also abundantly expressed at the intestine to 
oppose cholesterol and phytosterol absorption. Therefore, we measured the 
jejunum expression of G5G8 at both mRNA and protein levels as well as 
intestinal ABCA1, which contributes to intestinal HDL biogenesis [228]. Urso 
alone tended to decrease jejunum G5G8 at the mRNA level, but didn’t reach 
statistical significance (Fig 3.14A, B). However, immunoblot analysis indicated a 
marked reduction in G5G8 protein levels (Fig 3.14E). The combination of 0.005% 
EZ further reduced G5G8 both at mRNA and protein levels. We did not observe 
any change in NPC1L1 at the mRNA level (Fig 3.14C). The combination of Urso 
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and EZ also significantly decreased intestinal ABCA1 at both the mRNA and 
protein levels (Fig 3.14D, E). FPLC fractionation of serum indicated a reduction 
in HDL cholesterol and a modest shift toward smaller HDL particles (Fig 3.14F). 
Thus, the reduction in serum cholesterol concentrations is likely attributed to 
reduced ABCA1 and intestinally-derived HDL. 
 
 
 
Figure 3.14 EZ reduces intestinal G5G8 and ABCA1. (A-D) The mRNA 
expression for jejunum ABCG5, ABCG8, NPC1L1, and ABCA1 was determined 
by RT-PCR. n=6 for each group. (E) Immunoblot analysis of jejunum ABCG5, 
ABCG8, and ABCA1. (F) Serum (60 μl) from 4 mice in each group was 
fractionated by FPLC and analyzed for the distribution of cholesterol among 
lipoproteins. Horizontal bars indicated elution fractions for lipoproteins. Data 
are mean ± SEM. Differences were determined by one-way ANOVA followed by 
Bonferroni post-hoc tests. *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. 
 
Urso-EZ induced increase in FNS does not require G5G8. 
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To determine the extent to which the effect of Urso and Urso-EZ treatments were 
G5G8 dependent, WT and KO mice were maintained on a control diet, followed 
by Urso (0.3%), and then Urso-EZ (0.3%-0.005%). Each mouse served as its own 
control. 3-day fecal samples and blood were collected at the end of each 
treatment period. G5G8 KO mice presented slightly lower bile flow rates, but 
invariably lower rates of biliary cholesterol secretion (Fig 3.15A-B). In the 
absence of drugs, FNS were reduced by 52% in G5G8 KO mice compared to WT 
littermates (Fig 3.15C). Urso increased FNS in both WT and G5G8 KO mice by 
900% and 700%, respectively (Fig 3.15D). EZ produced a further 2-fold increase 
in both genotypes (Fig 3.15D). Thus, while FNS were invariably lower in G5G8 
KO mice, the drug-induced increase remained largely constant. Differences were 
not observed in serum cholesterol (not shown). 
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Figure 3.15 Urso-EZ induced increase in FNS does not require G5G8. G5G8 KO 
mice (n=4 both sexes) and their WT littermates (n=6 male and 7 female) were 
sequentially fed with control, 0.3% Urso, and 0.3% Urso plus 0.005% EZ for 14 
days. (A-B) Bile flow and biliary cholesterol secretion rates by sex. (C-D) FNS and 
the relative difference in fecal sterol loss normalized to controls. Another cohort 
of male and female KO and WT mice (n=3 of each gender and genotype) were 
fed a PSF diet or 0.3% Urso for 7 days. (E) The fractional cholesterol absorption 
was measured by stable dual isotope method and represented irrespective of sex. 
(F) The relative rates of intestinal epithelial cell proliferation and turnover were 
determined by BrdU staining. Sections were scored, 20 villi/crypts per mouse, 3 
mice per group, and the number of cells proliferating in jejunal crypts was 
determined. Data are expressed as mean ± SEM. Differences were determined by 
two-way ANOVA followed by Bonferroni post-tests (A, B, and E), a repeated 
measure two-way ANOVA using diet and genotype as factors followed by 
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Bonferroni post-hoc tests (C-D), and one-way ANOVA followed by Dunnett’s 
post-hoc comparisons (F). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
 
 
Possible factors contributing to fecal neutral sterol excretion include intestinal 
cholesterol absorption and epithelial cell sloughing. There was no cholesterol 
added to the PSF diet. Under this condition, fractional cholesterol absorption 
approached 90% in both WT and KO mice (Fig 3.15E). Urso reduced absorption 
in both genotypes. This may reflect the role of G5G8 in cholesterol absorption or 
the dilution of the cholesterol isotope associated with increased biliary 
cholesterol output. Effects were virtually identical in male and female mice (Fig 
3.16).  
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Figure 3.16 No sexual dimorphisms are observed in FNS, the relative 
difference in sterol loss, and cholesterol absorption. G5G8 KO mice (n=4 for 
both sexes) and their WT littermates (n=6 for male and 7 for female) were 
sequentially fed with control, 0.3% Urso, and 0.3% Urso plus 0.005% EZ for 14 
days. (A-B) FNS and the relative difference in fecal sterol loss were represented 
by sex. Another cohort of male and female KO and WT mice (n=3 for each 
gender and genotype) were fed a PSF diet or 0.3% Urso for 7 days. (C) The 
fractional cholesterol absorption was measured by stable dual isotope method 
and represented by sex. Data are expressed as mean ± SEM. Differences were 
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determined by a repeated measure two-way ANOVA using diet and genotype as 
factors followed by Bonferroni post-hoc tests (A-B) and two-way ANOVA 
followed by Bonferroni post-tests (C). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
The effects of Urso on intestinal epithelial cell proliferation and turnover are not 
known. To understand Urso’s effect in this process, we performed a BrdU 
incorporation study [221]. Anti-CD3 monoclonal antibody was used as a positive 
control by stimulating T cell-induced epithelial cell proliferation (18 hr) and 
increased crypt depth/villus blunting. In contrast, G5G8 deficiency failed to alter 
epithelial cell responses to Urso (Fig 3.12F, 14). These findings indicate that drug-
induced cholesterol elimination is independent of G5G8.  
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Figure 3.17 Intestinal epithelial cell proliferation and turnover in vehicle and 
0.3% Urso treated WT and G5G8 KO mice. Male KO (n=3) and their WT 
littermates (n=3) were fed a PSF diet or 0.3% Urso for 7 days. Mice were injected 
with BrdU 2 hrs before killing. Antibodies directed against CD3 were injected to 
male WT mice 18 hours prior to BrdU injection. (A) Formalin-fixed jejunal 
sections stained with hematoxylin and eosin (H&E) and immunohistochemistry 
allowed visualization of proliferating cells incorporated with BrdU in 
representatives of each group. Scale bar, 100 microns for H&E; 50 microns for 
BrdU staining. (B-C) Sections were scored, 20 villi/crypts per mouse, 3 mice per 
group. Villus height and crypt depth were determined. Data are mean ± SEM. 
Differences were determined by one-way ANOVA followed by Dunnett’s post-
hoc comparisons. 
 
DISCUSSION 
The major findings of the present study are that Urso increases G5G8 abundance 
and activity in liver and that Urso-EZ acts in an additive fashion to promote fecal 
sterol excretion in mice. While G5G8 is the primary route for biliary cholesterol 
secretion, our studies reveal a G5G8-independent pathway for cholesterol 
elimination stimulated by Urso and Urso-EZ combination treatments. Whether 
this is attributed to other biliary or non-biliary pathways, such as TICE, remains 
to be determined.  
Biliary cholesterol secretion represents an essential step of the RCT process 
which involves the transport of cholesterol from peripheral cells to the liver for 
secretion into bile and subsequent elimination in feces [120]. Accelerating RCT 
has long been a therapeutic goal in the treatment of atherosclerosis [144, 229]. 
However, the role of biliary cholesterol secretion in the development and 
severity of NAFLD is a relatively recent discovery. We have published the only 
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reports detailing G5G8 and biliary cholesterol secretion in the context of NAFLD 
[165, 167]. Consequently, studies to date have not examined accelerated biliary 
secretion as a therapeutic strategy in either preclinical models or humans in the 
treatment of NAFLD. Although G5G8 has been known to increase cholesterol 
excretion for over a decade, there has been little interest in drug development for 
this target. This is mainly because increasing biliary cholesterol secretion is 
expected to raise the cholesterol saturation index of bile and the risk for 
cholesterol gallstones. However, Urso is a hydrophilic bile acid with choleretic, 
cytoprotective, and antiapoptotic properties [230, 231]. It was originally used for 
cholesterol gallstone dissolution mainly because it reduces hydrophobicity of the 
bile acid pool and increases bile flow, two factors that oppose gallstone 
formation. Therefore, increasing G5G8 with Urso to increase biliary cholesterol 
secretion in the absence of increased risk of gallstone formation may be a viable 
therapeutic strategy to accelerate RCT. 
A number of preclinical studies and clinical trials have evaluated either Urso or 
EZ in the treatment of NAFLD or NASH. Results with Urso were mixed. Low-
dose Urso (13-15 mg/kg/day) reduced some markers of inflammation including 
serum alanine transaminase (ALT), but failed to significantly improve NASH in 
two separate studies [232, 233]. High-dose Urso (28-32 mg/kg/day) failed to 
reduce ALT at either 3 or 6 months in one trial (n=12); in a separate trial, high-
dose Urso lowered ALT levels by an average of 40% at 3, 6, 9 and 12 months and 
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normalized ALT values in 25% of patients compared to no reductions or 
normalizations in the placebo group [234, 235]. Although the numbers of studies 
and patients were limited, EZ monotherapy showed promise in the treatment of 
NAFLD. In a 6-month pre-/post treatment open-label trial in 10 patients, EZ 
reduced serum ALT, γ-glutamyl transpeptidase, plasma TGs and hepatic fat, but 
measures of insulin resistance were unchanged [236]. In the largest study to date 
(n=45) in a Japanese population, EZ reduced ALT at 12 months and resulted in 
modest, but significant reductions in steatosis, ballooning, and other indices of 
NAFLD by 24 months [135]. However, neither monotherapy is currently 
indicated in the treatment of NAFLD. The limited benefit may be due to the 
interdependent nature of biliary secretion and intestinal absorption with respect 
to cholesterol elimination. Therefore, a combination therapy that simultaneously 
increases biliary secretion and reduces cholesterol absorption may provide 
greater therapeutic benefit compared to Urso or EZ monotherapies. 
It was expected that Urso-EZ combination treatment would further stimulate 
fecal sterol loss and create a negative sterol balance or “cholesterol drain”. In the 
steady state, the extent of cholesterol loss is directly reflected by the rate of 
cholesterol synthesis. In the present study, no evidence supports an increase in 
whole body cholesterol synthesis except a modest increase in adrenal and jejunal 
HMGCS gene expression. In addition, feeding an Urso-containing diet led to a 
robust repression of hepatic CYP7A1 and CYP8B1. Thus, the observed increase in 
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FNS may reflect diversion of cholesterol away from bile acid synthesis into the 
G5G8 accessible pool, rather than the establishment of a cholesterol drain.  
The mechanism(s) by which Urso simultaneously increases G5G8 and suppresses 
bile acid synthesis is not known. It may be due to the stimulation of ileal FGF15, 
which acts on FGFR4/β-Klotho receptor complexes in liver to repress bile acid 
synthesis [185]. FGF15 also induces the protein synthesis in liver, but the effect of 
FGF15 on G5G8 is not known [185, 237]. Alternatively, recent studies suggest 
that the α5β1- integrin is a sensor for TUDCA that promotes choleresis [238, 239]. 
However, the effect of integrin signaling on G5G8 is not known. Therefore, it 
remains unclear whether the suppression of bile acid synthesis and the 
stimulation of G5G8 in response to Urso utilize common or independent 
mechanisms. If the mechanisms are independent, there may be a therapeutic 
window whereby biliary cholesterol secretion could increase to a greater extent 
than bile acid suppression in order to promote RCT. If not, other therapeutic 
approaches aimed to increase G5G8 and biliary cholesterol secretion would need 
to be developed in combination with EZ to accelerate RCT. However, such an 
approach may increase the risk of gallstone formation.  
Another intriguing observation in our present studies was that Urso and Urso-
EZ similarly increased FNS in G5G8 KO mice as in their WT littermates. This 
could be partially attributed to the most studied non-biliary route, TICE, which 
may account for approximately 33% of total fecal sterol loss in mice and is now 
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considered as an essential alternative route to the hepatobiliary pathway [227]. 
We did not simultaneously measure biliary and intestinal cholesterol secretion in 
our studies, nor did we evaluate to what extent biliary vs. non-biliary pathways 
contribute to the total fecal sterol loss. However, Urso and Urso-EZ in G5G8 
deficient mice may be useful tools in identifying novel biliary and non-biliary 
pathways for cholesterol elimination. 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Yuhuan Wang 2015 
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CHAPTER 4. ROLE OF FGF15/19 IN THE REGULATION OF ABCG5 ABCG8 
STEROL TRANSPORTER 
 
INTRODUCTION 
FGF15/19 is a metabolic hormone expressed in the enterocytes in the ileal 
segment of the small intestine. It has been recently discovered to play a crucial 
role in the cross-talk between liver and intestine in control of bile acid and 
energy homeostasis [183, 184, 186, 237, 240, 241]. Mouse FGF15 shares 
approximately 50% amino acid identity with its human orthologue, FGF19. 
However, they have similar tissue expression patterns, physiological functions, 
and pharmacological effects in mice [183-185]. One well-characterized action of 
FGF15/19 is to suppress bile acid synthesis [186, 188, 242, 243]. When 
(re)absorbed from the intestinal lumen, bile acids act on the FXR/RXR 
heterodimer to induce FGF15 expression. Secreted FGF15 acts on the liver via its 
receptor complex FGFR4/β-Klotho to repress CYP7A1 expression and bile acid 
synthesis.  
In Chapter 3, we showed that while Urso suppressed the major bile acid 
synthetic genes including CYP7A1 and CYP8B1, it increased expression of G5G8 
predominantly at the protein level in liver [244]. Consistently, both biliary 
cholesterol secretion and fecal neutral sterol output increased [244]. However, 
the mechanism(s) by which Urso simultaneously suppresses bile acid synthesis 
and increases G5G8 is (are) not known. Though Urso was reported to be a weak 
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agonist or even a partial antagonist for FXR, our results demonstrated that ileal 
FGF15 mRNA expression was strikingly increased in response to Urso treatment 
[244-246]. The repression of bile acid synthesis may at least in part be due to the 
stimulation of ileal FGF15, which acts on FGFR4/β-Klotho receptor complexes in 
liver to activate the downstream signaling cascade. Whether FGF15 would 
concurrently have a direct effect on G5G8 is unknown. However, our results 
from Chapter 3 provide very positive evidence. 
Additional evidence also supports the hypothesis that FGF15/19 directly 
regulates G5G8 protein abundance. Beyond suppressing bile acid synthesis, 
FGF15/19 is thought to promote gallbladder filling by increasing cAMP levels 
[187]. Intriguingly, the cAMP signaling machinery has recently been discovered 
to mediate the trafficking of G5G8 to the bile canalicular membrane in response 
to hypernutrition. Administration of a protein kinase A inhibitor decreases G5G8 
protein expression, whereas injection of a cAMP analog transiently increases 
their levels [190].  
In this chapter, two additional mouse models were tested to confirm the positive 
correlation between ileal FGF15 expression and hepatic G5G8 protein 
abundance. One is Asbt KO mouse model. Dawson and coworkers generated the 
Asbt KO mice to decipher the in vivo functions of Asbt in bile acid homeostasis 
[247, 248]. In this mouse model, the disruption of Asbt blocks the apical uptake of 
bile acids, thereby resulting in decreased expression of ileal FGF15 and reduced 
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entry of bile acids into enterohepatic cycling, both of which are thought to 
contribute to increased bile acid synthesis. However, the protein expression of 
hepatic G5G8 has never been tested. The other one is LIRKO mouse model, in 
which hepatic G5G8 protein levels and biliary cholesterol secretion are elevated. 
However, the ileal FGF15 expression has never been reported.  
Then the hypothesis was directly tested by determining the G5G8 protein 
abundance and biliary cholesterol secretion in mice administered with 
recombinant human FGF19. As predicted, FGF19 elevated G5G8 protein levels 
specifically in liver not in intestine. It also increased biliary cholesterol secretion 
in the absence of increasing the cholesterol saturation index (CSI). This is likely 
due to the proportional increase in the biliary secretion rates of both 
phospholipids and bile acids.  
MATERIALS AND METHODS 
Chemicals, reagents and antibodies 
General chemicals were purchased from Sigma, immunoblotting reagents from 
Thermo/Pierce, real-time PCR reagents from Applied Biosystems. The chicken 
anti-G5 polyclonal antibody and the monoclonal antibody directed against G8 
were previously reported [244]. Total and phospho-eIF2α antibodies were 
purchased from Cell Signaling. The ABCA1 and SR-BI antibodies were 
generously provided by Mason Freeman (Harvard Medical School) and Deneys 
R. van der Westhuyzen (University of Kentucky), respectively. The β-actin 
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antibody was purchased from Sigma. Calnexin and GRP78 antibodies were 
purchased from Nventa (San Diego, CA). The antibody to Calriticulin was 
purchased from Stressgen. 
Animal husbandry 
Male C57BL/6J (Stock #000664) mice at an age of 8 weeks were purchased from 
the Jackson Laboratory (Bar Harbor, ME). Upon arrival mice were allowed to 
acclimatize for one week prior to initiation of studies. Mice were housed in 
individually ventilated cages in a temperature-controlled room with a 14:10 light: 
dark cycle and provided with enrichment in the form of acrylic huts and nesting 
material. Mice were maintained on standard rodent chow (Harlan Teklad 2014S). 
All animal procedures conform to PHS policies for humane care and use of 
laboratory animals and were approved by the institutional animal care and use 
committee at the University of Kentucky. All surgery was performed under 
anesthesia, and all efforts were made to minimize suffering. 
Human recombinant FGF19 injection experiment 
Human recombinant FGF19 (CYT-700) was purchased from ProSpec (Protein-
Specialists). Vehicle or FGF19 (1 μg/g body weight) was injected into mice 
intraperitoneally twice every four hours in a total volume of 200 μl of PBS. All 
mice were placed in clean cages with full access to water, but without food. Four 
hours after a second injection of FGF19, mice were sacrificed. Basal bile, liver, 
and three segments of the small intestine were collected as described previously 
[244].  
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Immunoblot and quantitative Real-time PCR 
The preparations of proteins, SDS-PAGE and immunoblotting were conducted as 
previously described [166, 249]. Total RNAs were extracted from each liver using 
RNA STAT-60 (Tel-Test, Inc) and subjected to cDNA synthesis with iScript 
cDNA Synthesis Kit (BIO-RAD, Hercules, CA). To determine relative abundance, 
RT-PCR was conducted using SYBRGreen as detector on Applied Biosystem 
7900HT fast-Real Time PCR System (Carlsbad, CA).  
Serum and biliary lipid analysis 
Total cholesterol in serum, as well as cholesterol and phospholipids in 
gallbladder bile, were determined using commercial colorimetric-enzymatic 
assays (Wako Chemicals, Richmond, VA). The quantitation of total bile acids  in 
bile was performed enzymatically by measuring 3α-hydroxy bile acids as 
previously described [222]. 
Statistical analysis 
All statistical analyses were conducted using GraphPad Prism. Data are 
expressed as mean ± SEM. Data were analyzed by two-tailed t-test. Differences 
were considered significant at P < 0.05. 
 
RESULTS 
The liver tissues of Asbt KO mice and their WT controls were generously 
provided by Paul Dawson (Emory University). Hepatic protein levels of G5 and 
G8 were analyzed by immunoblotting (Fig 4.1). As expected, we observed 
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reduced hepatic G5G8 protein abundance in Asbt KO mice compared with their 
WT controls (Fig 4.1). This positively correlates with the low expression of FGF15 
in ileal enterocytes in Asbt KO mice. However, we cannot exclude the possibility 
that the increased bile acid synthesis tightly regulated via the classical feedback 
mechanism may deprive the G5G8 accessible pool of cholesterol. 
 
Figure 4.1 Asbt KO mice present lower G5G8 abundance in liver. Male WT and 
Asbt KO mice were maintained on a prepared basal diet [248]. Hepatic levels of 
G5 and G8 protein expression were determined by immunoblotting. Membrane 
preparations were blotted for β-actin as loading controls.  
 
We then looked at the association between ieal FGF15 expression and hepatic 
G5G8 protein levels in LIRKO mice. We selectively deleted the hepatic insulin 
receptor from insulin receptor-floxed mice using adeno-associated virus (AAV) 
expressing a Cre recombinase (AAV-Cre) driven by the albumin promoter and 
generated the LIRKO mouse model. We confirmed the deletion of insulin 
receptor and the increase of hepatic G5G8 abundance by immunoblotting 
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analysis (Fig 4.2B). Consistently, we observed a significant increase in ileal FGF15 
expression in LIRKO mice compared with their controls (Fig 4.2A).  
 
Figure 4.2 Elevated hepatic G5G8 abundance of LIRKO mice is associated with 
stimulated ileal FGF15 expression. Male insulin receptor (IR) floxed mice at 8-
week old age were injected through the tail vein with 5x1011 particles of adeno-
associated virus encoding Cre-recombinase (AAV-Cre) or empty AAV vectors. 
Two weeks following virus infection for hepatic insulin receptor deletion, mice 
were sacrificed. The liver and ileal segment of intestine were harvested for IR, 
G5G8 immunoblotting and ileal FGF15 mRNA expression, respectively.  
 
 
Next, we directly tested if FGF15/19 could acutely increase hepatic G5G8 
abundance. Due to the decreased stability of recombinant FGF15, we used the 
human orthologue, FGF19, for our studies. Body weight tended to decrease after 
FGF19 treatment, but didn’t reach significant differences (Fig 4.3A). No change 
was noted for liver weight (Fig 4.3A). One major effect of FGF19 is to suppress 
bile acid synthesis in liver via a mechanism involving FGFR4 activation and SHP 
induction and stability [186, 250-252]. As previously reported, FGF19 
significantly reduced the mRNA expression of CYP7A1 whereas it induced that 
of SHP (Fig 4.3B). Similar results were observed for CYP8B1 and CYP27A1. 
However, no decrease was detected in CYP7B1. To determine if FGF19 would 
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directly regulate G5G8, we measured G5G8 expression at both mRNA and 
protein levels in liver by RT-PCR and immunoblotting analysis, respectively (Fig 
4.3B-C). FGF19 tended to increase the mRNA expression of both G5 and G8, but 
only reached statistical significance for G8 (Fig 4.3B). However, immunoblotting 
analysis confirmed a marked increase in both G5 and G8 protein expression (Fig 
4.3C). This was observed only in liver not in intestine (Fig 4.3D).  
 
Figure 4.3 FGF19 increases hepatic G5G8 at protein levels. Male C57BL/6J mice 
at an age of 8 weeks were treated with PBS or FGF19 (1 μg/g) by i.p. injection 
twice every four hours. (A) Body weight and liver weight. (B) Relative mRNA 
levels of major transcription factors, enzymes, and transporters involved in bile 
acid metabolism in liver. (C) Hepatic and (D) jejunal levels of G5G8 protein 
expression were determined by immunoblotting. Membrane preparations were 
blotted for β-actin as controls. Data are presented as mean ± SEM. Differences 
between FGF19- and PBS-treated groups were determined by two-tailed t-test. a: 
p<0.05, b: p<0.01, c: p<0.001, and d: p<0.0001. 
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FGF19-treated mice displayed similar rates of hepatic bile flow but significantly 
elevated total bile lipid (Fig 4.4A). Hepatobiliary secretion rates of lipids 
including cholesterol, phospholipid, and bile salt under basal conditions were 
calculated from the product of bile flow and lipid concentration. Significant 
increases were not only observed in bile salt secretion rates in FGF19-treated 
mice, but also in phospholipid and cholesterol during the 30-min collection 
period (Fig 4.4B). However, no differences were detected in bile salt, 
phospholipid, or cholesterol compositions when we expressed the biliary lipid 
data proportionally (Fig 4.4C). We then measured the CSI of gallbladder bile (Fig 
4.4D). Both groups exhibited CSI<1 in gallbladder bile indicating that the 
administration of FGF19 increases biliary cholesterol secretion without 
increasing the risk for gallstone formation. 
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Figure 4.4 FGF19 increases the biliary secretion rates of cholesterol, 
phospholipids (PL), and bile salts (BS). (A) Hepatic bile flow and total lipids 
concentrations. (B) Biliary lipid secretion rates under basal conditions. 
Gallbladder was cannulated and basal bile was collected for 30 min. (C) Biliary 
lipid composition (mole %). (D) Cholesterol saturation index of gallbladder bile 
was calculated from the critical tables. Data are presented as mean ± SEM. n=6-7 
for each group. Differences between FGF19- and PBS-treated groups were 
determined by two-tailed t-test. b: p<0.01 and c: p<0.001. 
 
To determine if increased biliary cholesterol secretion stimulated by FGF19 
changed the hepatic cholesterol metabolism, we measured the mRNA expression 
of major genes involved in cholesterol synthesis and efflux (Fig 4.5A). FGF19 
moderately increased SREBP2 and HMGCS with a tendency to increase HMGCR 
at the mRNA level, indicating that the increased biliary cholesterol secretion 
provides a driving force to cholesterol synthesis (Fig 4.5A). Even though we 
observed a significant increase in both ABCA1 and SR-BI at mRNA level, we 
didn’t detect any difference in their protein expression by immunoblotting 
analysis (Fig 4.5A-B). This is likely due to that an eight-hour interval is not long 
enough to allow us to see changes of ABCA1 and SR-BI at the protein level. 
FGF19 had no effect on serum total cholesterol or phospholipids (Fig 4.5C). 
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Figure 4.5 FGF19 increases the expression of major genes in cholesterol 
synthesis and efflux at the mRNA level. (A) The mRNA expression for major 
genes involved in de novo cholesterol synthesis and efflux was determined by 
RT-PCR. n=5-7. (B) Immunoblot analysis of hepatic SR-BI and ABCA1. (C) Total 
cholesterol and phospholipids (PLs) concentrations in serum. n=6 for each group. 
Data are presented as mean ± SEM. Differences between FGF19- and PBS-treated 
groups were determined by two-tailed t-test. a: p<0.05, b: p<0.01, c: p<0.001, and 
d: p<0.0001. 
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To determine if FGF19 altered the TG metabolism in liver, we measured the 
mRNA expression of the major genes involved in in lipogenesis and fatty acid 
oxidation (Fig 4.6). Results showed that a double-injection of FGF19 significantly 
suppressed the expression of SREBP1c, malic enzyme 1(ME1), and acetyl-CoA 
carboxylase 2 (ACC2). This confirmed the role of FGF19 in fatty acid synthesis 
and oxidation. 
 
Figure 4.6 FGF19 reduces lipogenesis in liver. The mRNA expression for major 
genes involved in fatty acid synthesis and oxidation was determined by RT-PCR. 
n=5-7 for each group. Data are presented as mean ± SEM. Differences between 
FGF19- and PBS-treated groups were determined by two-tailed t-test. a: p<0.05 
and c: p<0.001. 
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DISCUSSION 
The major findings of the study are that FGF15/19 increases the expression of 
G5G8 predominantly at the protein level as well as biliary cholesterol secretion. 
This effect is only restricted to G5G8 in liver other than intestine. Interestingly, 
the proportional increase in both biliary phospholipids and bile acids explains 
the unaltered CSI. Moreover, FGF19 also suppresses the expression of major 
lipogenic genes and those involved in fatty acid oxidation.  
A mouse model of liver-specific insulin resistance in the absence of obesity 
(LIRKO) has been previously published and the impact of selective insulin 
receptor deletion in liver on several features of sterol homeostasis was reported 
[48, 193]. Biddinger and coworkers proposed two distinct mechanisms that tie 
links between gallstones and MetS. While increasing hepatic G5G8 via a 
mechanism involving the disinhibition of FOXO1, hepatic insulin resistance 
decreases expression of major bile acid synthetic genes resulting in a lithogenic 
bile salt profile. Our results confirmed the stimulation of ileal FGF15 in LIRKO 
mice. As the roles of FGF15/19 in bile acid homeostasis have been widely 
appreciated, FGF15 may mechanistically contribute to the repressed expression 
of major bile acid synthetic genes and the elevated G5G8 abundance in LIRKO. 
Remarkably similar as insulin, FGF15/19 also stimulates hepatic glycogen 
synthesis and represses gluconeogenesis [237, 253]. In addition, FGF15 signaling 
has also been previously shown to decrease hepatic FOXO1 activity through the 
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phosphorylation of PI3K [242]. The stimulated FGF15 expression in LIRKO mice 
may not only explain the overall suppressed bile acid synthetic genes and 
increased G5G8 but also function as a compensatory mechanism to counteract 
the loss of insulin signaling.  
Controversial results have been previously reported for the roles of FGF15/19 in 
lipogenesis [237, 240, 241, 254]. Bhatnagar and coworker investigated the roles of 
FGF19 in modulating hepatic fatty acid synthesis via primary hepatocyte 
cultures with recombinant FGF19 and concluded that FGF19 suppressed insulin-
stimulated fatty acid synthesis and SREBP1c expression [254]. Stewart’s group 
generated the FGF19 transgenic mice and reported that these mice had increased 
energy expenditure and decreased liver TGs which could be partially due to the 
decreased ACC2 expression in liver [240]. They also observed similar phenotypes 
in ob/ob and HF diet-fed FVB mice injected with FGF19 [241]. However, when Kir 
and coworker overnight-fasted C57BL/6 mice and injected them subcutaneously 
with FGF19, they didn’t observe any change in lipogenic gene expression 6 hours 
following FGF19 injection [237]. Our results align with the previous observations 
but against Kir’s. The roles of FGF15/19 in lipogenesis need further 
investigation.  
Cholic acid is a strong FXR agonist that stimulates FGF15 expression and 
activates its downstream signaling cascade. Watanabe and coworker reported 
that cholic acid reduced the expression of SREBP1c and other lipogenic genes, 
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lowered hepatic and serum TG levels. Moreover, it also attenuated LXR agonist-
stimulated lipogenesis [255]. Whether the effects of cholic acid on lipogenesis 
and TG homeostasis are dependent on FGF15 signaling has never been 
addressed. However, this may provide indirect evidence that as opposed to 
insulin, which promotes lipogenesis, FGF15/19 may mitigate the induction of 
hepatic lipogenesis. 
Overall, the overlapping but distinct actions of FGF15/19 and insulin may 
promise the use of FGF15/19 as a therapeutic strategy in the treatment of 
diabetes or in combination with LXR agonists to correct atherosclerotic 
cardiovascular disease. However, the potential use of FGF19 as a chronic 
treatment may have concerns. Long-term treatments of FGF19 have been 
implicated to associate with liver tumors or hepatocellular carcinoma [256, 257]. 
Strategies aiming at developing synthetic FGF19 variants that preserve the 
metabolic effects of FGF19 but silence its mitogenic effects need to be explored.  
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
 
Summary of major findings 
The goal of this dissertation thesis is to understand the mechanisms responsible 
for the post-transcriptional regulation of sterol transporter G5G8 in vivo such 
that appropriate therapeutics could be employed to target cholesterol elimination 
pathways to oppose MetS and NAFLD and prevent the onset and progression of 
CVD. 
In Chapter 2, acute replacement of letpin in ob/ob mice, liver-specific ablation of 
leptin receptor in lean mice, and hepatic vagotomy in diet-induced obese mice all 
failed to alter hepatic G5G8 protein levels. Therefore, the reduction of G5G8 in 
leptin axis deficient mice is not a direct consequence of leptin signaling. 
Alternatively, G5G8 may be decreased in ob/ob and db/db mice due to ER 
dysfunction, the site of G5G8 complex assembly. Our data showed that 
overexpression of the ER chaperone GRP78 alleviated ER stress and reduced 
expression of lipogenic genes and plasma TGs in db/db mice. As we 
hypothesized, both G5 and G8 protein levels increased as did total biliary 
cholesterol in the absence of changes in G5 or G8 mRNAs.  
Leptin axis deficient mice (ob/ob and/or db/db) have been frequently used in the 
pathogenic studies of MetS and NAFLD. Available data from previous studies 
using these mice establish the role of G5G8-mediated biliary cholesterol secretion 
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in opposing many risks factors for MetS and NAFLD, such as insulin resistance, 
elevated plasma TG, and ER stress. Alleviation of ER stress by TUDCA and 
GRP78 overexpression both restore insulin sensitivity and hepatosteatosis. 
TUDCA has been reported to increase G5G8 protein abundance and biliary 
cholesterol secretion. In Chapter 2, we conclude that alleviation of ER stress by 
GRP78 also rescues G5G8 and elevates biliary cholesterol secretion. This not only 
suggests a reciprocal relationship between ER function and G5G8-mediated 
biliary cholesterol secretion, but also establishes a proof-of-principle that 
improving ER function rescues G5G8 and may account for a potential approach 
to target G5G8 activity in the treatment of metabolic disease. 
Results in Chapter 3 demonstrated that a FDA approved drug for the treatment 
of primary biliary cirrhosis and dissolution of gallstones, Urso, 
pharmacologically increased hepatic G5G8 protein expression and both biliary 
and fecal sterols in a dose-dependent manner. Given the interdependent 
relationship between liver and intestine for cholesterol elimination from the body, 
we proposed that a combined therapy aimed at increasing biliary cholesterol 
secretion and simultaneously reducing intestinal absorption is likely to act 
additively in enhancing cholesterol elimination from the body. Indeed, our data 
demonstrated that EZ, an inhibitor of intestinal cholesterol absorption, produced 
an additive and dose-dependent increase in FNS elimination in the presence of 
Urso. The stimulatory effect in response to Urso or Urso-EZ treatments was not 
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G5G8 dependent. This may be partially attributed to the non-biliary route for 
cholesterol elimination. Little has been known about the mechanisms responsible 
for the non-biliary pathway. Urso and Urso-EZ in G5G8 KO mice may provide 
very useful tools in identifying novel biliary and non-biliary pathways for 
cholesterol elimination.  
We originally expected that in the absence of cholesterol feeding, the combined 
pharmacological therapy would create a net negative sterol balance or 
“cholesterol drain” that significantly drives the rate of whole body cholesterol 
synthesis. However, we only detected a very modest increase in adrenal and 
jejunal HMGCS gene expression. This indicates that Urso, as a pharmacological 
approach to target G5G8, increases biliary and fecal sterol excretion. However, 
this comes at the expense of diverting cholesterol away from bile acid synthesis 
into the G5G8 accessible pool. Though such an effect of Urso dampens our 
enthusiasm for the Urso-EZ combination therapy, it sheds light on another 
regulator of G5G8, FGF15/19. 
Beyond increasing hepatic G5G8 protein expression and biliary cholesterol 
secretion, Urso also stimulates the ileal FGF15 expression in mice. In Chapter 4, 
stimulated ileal FGF15 expression in LIRKO and reduced hepatic G5G8 protein 
levels in Atsb KO mice both indicated the previous unrecognized role of 
FGF15/19 in the regulation of G5G8 and its activity. Indeed, this was 
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subsequently confirmed by our results from the direct test of recombinant 
human FGF19 on G5G8. 
Future directions 
In this dissertation, we postulate, for the first time, a concept of “cholesterol 
drain” achieved by simultaneously increasing G5G8-mediated biliary cholesterol 
secretion and inhibiting intestinal absorption for the treatment of metabolic 
disease. Moreover, our work presented in this dissertation also demonstrate, for 
the first time, that recombinant human FGF19 increases hepatic G5G8 abundance 
and activity, and thereby uncovering a previously unappreciated link between 
FGF15/19 and sterol flux. However, many questions remain to be addressed in 
the future.  
In Chapter 3, the mechanism(s) by which Urso simultaneously increases G5G8 
and suppresses bile acid synthesis is not known. Previous studies and our results 
from Chapter 4 imply that FGF15/19 is likely to account for the Urso’s dual 
effects and work more efficiently than Urso to oppose metabolic disease in 
combination with EZ. Supportive rationales and evidence are listed below. 
Bile acid synthesis is tightly regulated via both a classical feedback mechanism 
and FGF15/19 signaling to ensure that sufficient amounts of cholesterol are 
catabolized to bile acids so as to facilitate biliary cholesterol secretion and 
provide adequate emulsification for lipid absorption in the intestine. Urso, as a 
bile acid itself, represses the bile acid synthesis via dual mechanisms. The Urso-
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stimulated biliary and fecal sterol loss comes at the expense of diverting 
cholesterol away from bile acid synthesis into biliary secretion. This is reflected 
by the unaltered expression of major genes involved in the de novo cholesterol 
synthesis shown in Chapter 3. However, treatment of FGF15/19, though 
suppresses bile acid synthesis, may still adapt to the negative feedback 
mechanism to catabolize excess hepatic cholesterol and compensate the bile acid 
loss. Our results from Chapter 4 demonstrate that the administration of 
recombinant FGF19 itself is sufficient to stimulate the expression of major genes 
involved in cholesterol biosynthesis in liver. Additionally, FGF19 stimulates 
G5G8-mediated biliary cholesterol secretion without increasing cholesterol 
saturation index.  
Moreover, insulin resistance is widely considered as the central source for the 
pathogenesis of MetS and NAFLD. FGF15/19 possesses very similar effects as 
insulin in stimulating hepatic glycogen synthesis and repressing 
gluconeogenesis, but likely an opposite effect in lipogenesis. The overlapping but 
distinct effects of FGF15/19 make it very promising in the treatment of metabolic 
disease. 
Given that the prolonged exposure of FGF19 has been implicated in liver 
tumorigenesis or hepatocellular carcinogenesis, nontumorigenic FGF19 variants 
that preserve the metabolic effects of FGF19 should be used in combination with 
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EZ for relatively long-term treatments. One of such FGF19 variants that have 
been tested in both in mice and humans is M70 [258, 259]. 
In mouse liver, FGF15 acts through a cell surface receptor complex composed of 
FGFR4 and βKlotho and promotes gallbladder filling by increasing cAMP levels. 
The cAMP analog has been recently shown to enhance canalicular trafficking of 
G5G8. Thus, the FGF15/FGF19-FGFR4-cAMP signaling pathway is likely to 
account for the regulation of hepatic G5G8 abundance and activity. Future 
investigation of the hepatic G5G8 protein abundance and biliary cholesterol in 
FGF15-KO mice, FGFR4-KO and β-Klotho-KO mice will be necessary. 
The work presented in this dissertation is mainly focused on targeting the classic 
G5G8-mediated biliary pathway to oppose metabolic disease. However, there is 
evidence that non-G5G8-mediated biliary route and non-biliary route may also 
contribute to the cholesterol elimination. The molecular components involved in 
these pathways are not known. Urso and Urso-EZ treatments in G5G8 KO mice 
suggest the G5G8-independent pathway for cholesterol elimination. Whether 
FGF15/19-stimulated biliary cholesterol secretion is dependent on G5G8 and 
whether FGF15/19 stimulates the non-biliary pathway for cholesterol 
elimination, e.g., TICE, would be interesting questions needed to be addressed 
by future studies.  
 Copyright © Yuhuan Wang 2015 
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APPENDICES 
ABBREVIATIONS 
AAV: adeno-associated virus 
AAV-Cre: adeno-associated virus expressing a Cre recombinase 
ACAT2: acetyl-CoA acetyltransferease 2 
ACC: acetyl-CoA carboxylase  
AdCre: adenovirus encoding Cre-recombinase  
AdGRP78: adenovirus encoding GRP78 
ALT: alanine aminotransferase  
apoB: apolipoprotein B  
ASBT: apical sodium-dependent bile transporter  
AST: aspartate aminotransferase  
ATF6: activating transcription factor 6  
ATP III: Adult Treatment Panel III 
BSEP: bile salt export protein BrdU: bromodeoxyuridine  
BSTFA: N, O-Bis (trimethylsilyl) trifluoroacetamide  
cAMP: cyclic adenosine monophosphate  
CE: cholesteryl ester 
CETP: cholesteryl ester transfer protein  
CHOP: C/EBP homologous protein  
CM: chylomicron  
CMR: chylomicron remnant  
ChREBP: carbohydrate response element-binding protein  
CRP: C-reactive protein 
CSI: cholesterol saturation index 
CVD: Cardiovascular disease  
CYP7A1: cholesterol 7alpha-hydroxylase. 
CYP7B1: 25-hydroxycholesterol 7-alpha-hydroxylase  
CYP8B1: sterol 12-alpha-hydroxylase  
CYP27A1: sterol 27-hydroxylase  
db/db: leptin receptor deficient mice 
eIF2α: eukaryotic initiation factor 2 alpha  
ER: Endoplasmic reticulum  
EZ: Ezetimibe  
FAS: fatty acid synthase 
FC: free cholesterol 
FGF: fibroblast growth factor 
FGFR: fibroblast growth factor receptor 
FOXO: forkhead box protein O 
FPLC: fast protein liquid chromatography  
FXR: farnesoid X receptor  
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G5G8: ABCG5 ABCG8  
GRP78: the 78-kD glucose-regulated/binding immunoglobulin protein  
HCC: hepatocellular carcinoma 
HDL: high-density lipoprotein  
HDL-C: high-density lipoprotein cholesterol 
HF: high fat 
HMG-CoA: 3-hydroxy-3-methylglutary CoA 
HMGCR: HMG-CoA reductase 
HMGCS: HMG-CoA synthase 
HNF4α: hepatocyte nuclear receptor 4α 
IBABP: ileal bile acid-binding protein  
IDF: International Diabetes Federation 
IL-6: interleukin-6  
Insig: insulin-induced gene proteins  
IPP: isopentenyl pyrophosphate  
IRE1: inositol-requiring enzyme 1  
IRS: insulin receptor substrate  
JNK: c-Jun N-terminal kinase  
KO: knockout  
LCAT: lecithin-cholesterol acyltransferase  
LDL: low-density lipoprotein 
LDL-C: low-density lipoprotein cholesterol 
LDLR: low-density lipoprotein receptor 
LIRKO: liver-specific insulin receptor knockout  
LPL: lipoprotein lipase  
LRH-1: orphan nuclear receptor liver receptor homolog-1  
LRP-1: low-density lipoprotein receptor related protein 1  
LXR: liver X receptor 
NAFLD: Nonalcoholic fatty liver disease  
NASH: Nonalcoholic steatohepatitis 
NEFA: nonesterified fatty acid 
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells  
NTCP: sodium sodium (Na+)-taurocholate cotransporting polypeptide 
NPC1L1: Niemann-Pick C1-like 1 
MAP: mitogen activated protein  
MetS: Metabolic syndrome 
PBA: Phenyl butyric acid  
PAI-1: plasminogen activator inhibitor-1  
PERK: protein kinase RNA-like endoplasmic reticulum kinase  
PI3K: phosphatidylinositol 3-kinase  
PPAR: peroxisome proliferator-activated receptor alpha 
OATP: organic anion transporters  
Ob/ob: leptin deficient mice 
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ObR: leptin receptor  
PSF: plant sterol-free 
RCT: Reverse cholesterol transport  
ROS: reactive oxygen species  
SCAP: SREBP cleavage-activating protein  
SHP: small heterodimer partner  
SR-BI: scavenger receptor class B member 1  
SREBP: sterol regulatory element binding protein  
STZ: thiazolidinedione  
TICE: trans-intestinal cholesterol excretion 
TNFα: tumor necrosis factor-alpha  
TUDCA: tauroursodeoxycholic acid 
UDCA: ursodeoxycholic acid  
UPR: unfolded protein response 
Urso: ursodiol  
VLDL: very low density lipoprotein  
WT: wild-type 
XBP1: X-box binding protein 1  
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